  PhII-107, NCI# 8628  
  8.21.17 v i SUMMARY OF CHANGES  
 
Date:   August 21, 2017  
Document:  NCI Protocol # 8628, PhII -107: “A Randomized Phase II Study of Sequential 
Biotherapy with Aflibercept and High Dose IL -2 versus High Dose IL -2 alone in 
Patients with Inoperable Stage III or Stage IV Melan oma: Efficacy and Biomarker 
Study .” 
Note:   The following is a Summary of Changes between the 12.31.15 and 8.21.17  
version of the protocol  
 
Section  Description of Change  (v. 12.31.15 and v. 8.21.17 ) 
Face page  Added August 21, 2017  to the list of protocol versions  and updated the footer . 
Updated the principal investigator and other participating investigators.   
  PhII-107, NCI# 8628  
  8.21.17 v 1 NCI Protocol #:   8628  
 
Local Protocol #:   PhII-107 
 
TITLE:  A Randomized Phase II Study of Sequential Biotherapy with Afliber cept and High 
Dose IL -2 versus High Dose IL -2 alone in Patients with Inoperable Stage III or Stage IV 
Melanoma: Efficacy and Biomarker Study    
 
Coordinating Center:  California Cancer Consortium Data Coordinating Center  
 City of Hope  
 1500 E. Duarte Road, Duarte, California 91010  
 Phone:  626 -256-HOPE(4673), extension 65928  
 Fax:      626 -256-8654  
    Email:  cccp@coh.org   
 
*Principal Investigator:  Ahmad A. Tarhini, MD, PhD 
Cleveland Clinic Taussig Cancer Institute  
Taussig  Cancer Center  
500 Euclid Ave CA6 -157 
Cleveland, OH 44195  
Phone: 216-636-0200  
Fax:     216-444-9464  
E-mail: tarhina1@ccf.org    
 
Co-Investigators:  John Kirkwood, MD  
 University of Pittsburgh Cancer Institute  
 Hillman Cancer Center Research Pavilion  
     5117 Centre Ave, Suite 1.32  
     Pittsburgh, PA 15213  
     Telephone: 412-623-7707  
     Fax: 412-623-7704  
     E-mail: kirkwoodjm@upmc.edu  
  
    Lawrence Flaherty, MD  
    Professor of Medicine, Medical Director, Clinical Trials Office  
Barbara Ann Karmanos Cancer Institute  
4100 John R  
Detroit, MI 48201  
    Telephone: 313 -576-8725    
    Fax: 313 -576-8726  
Email:  flaherty@karmanos.or g 
    
        
 
 
 Kim Margolin , MD  
  PhII-107, NCI# 8628  
  8.21.17 v 2 City of Hope National Medical Center  
1500 E. Duarte Rd  
Duarte, CA 91010 -3000  
Phone:  626-218-3110  
Fax: 626 -301-8233  
E-mail:  kmargolin@coh.org  
 
Scott Christensen, M.D.  
UC Davis Cancer Center  
4501 X Street  
Sacramento, CA  95 817 
Telephone:   916-734-3772  
Fax:  916-734-7946  
E-mail:  scott.christensen@ucdmc.ucdavis.edu  
 
    Heinz -Josef Lenz, MD  
    USC/Norris Comprehensive Cancer Center  
    1441 Eastlake Avenue  
    Los Angeles, CA  90033  
    Phone:  323 -865-3955  
    Fax:  323 -865-0061  
    Email:  lenz@usc.edu  
 
    Chandra Belani, MD  
    Penn State Milton S. Hershey Medical Center  
    500 University Drive, H072  
    Hershey, PA  17033  
    Phone:  717 -531-1078  
    Fax:  717 -531-0002  
    Email:  cbelani@psu.edu  
 
Hussein Tawbi, MD, MSc  
UPCI Sarcoma Program Director  
UPCI -CTRC University of Pittsburgh Cancer Institute  
5150 Centre Avenue Pittsburgh, PA 15232  
Telephone: 412 -692-2600  
Fax: 412 -648-6579  
E-mail: tawbih@upmc.edu   
 
     Lisa Butterfield, PhD (not a treating physician)  
Director, UPCI Immunologic Monitoring and Cellular Products 
Laboratory  
University of Pi ttsburgh, Hillman Cancer Center  
Hillman Cancer Center  
5117 Centre Avenue  
Pittsburgh, PA 15213  
  PhII-107, NCI# 8628  
  8.21.17 v 3 Telephone: 412 -623-1418  
Fax: 412 -624-0264  
Email: butterfieldl@upmc.edu    
      
 Lionel David Lewis , MD  
Dartmout h Hitchcock Medical Center  
One Medical Center Drive  
Lebanon, NH 03756  
Telephone:   603-650-8685  
Email: lionel.lewis@dartmouth.edu   
 
Theodore  F. Logan, MD  
Associate Professor of Clinical Medicine  
Indiana Univ ersity Health  
535 Barnhill Dr., RT 473  
Indianapolis, IN 46202  
Phone: (317) 948 -7576  
Fax: (317)274 -8022  
Email: tlogan@iu.edu    
 
Thomas Olencki, D.O.  
Kari Kendra, MD  
Ohio State University  
320 West 10th Avenue  
A433A Starli ng Loving Hall  
Columbus, Ohio 43210  
Phone: 614 -293-4680  
Fax: 614 -293-7525  
Email: Thomas.Olencki@osumc.edu  
Email:  Kari.Kendra@osumc.edu   
 
Saby George MD, FACP  
Assistant Professor of Medicine and Oncology Roswell Park 
Cancer Institute  
Elm and Carlton Streets  
Buffalo, NY 14263  
Phone :  (716) 845 -8387  
Fax: (716) 845 -3519  
Email:  Saby.George@RoswellPark.org   
 
Sunandana Chandra , MD  
Robert H. Lurie Comprehensive Cancer Center  
Northwestern Memorial Hospital  
676 N. St. Clair, Suite 850  
Chicago, IL 60611  
Phone : (312) 695 -0990  
  PhII-107, NCI# 8628  
  8.21.17 v 4 Email:  sunandana.chandra@northwestern.edu   
 
Igor Puzanov, MD  
Vanderbilt University Medical Center  
2220 Pierce Avenue  
777 Preston Research Building  
Nashville, TN 37232 -6307  
Telephone: 615 -936-6938  
Fax: 615 -936-5850  
Email: igor.puzanov@vanderbilt.edu  
 
David Lawson, MD  
Emory University  
1365C Clifton Road  
Atlanta, GA 30322  
Phone 404 -778-1900  
Fax 404-778-5676  
Email: dlawson@emory.edu  
 
Henry Koon, MD  
UH Case Medical Center  
Department of Medicine -Hematology and Oncology  
11100 Euclid Ave  
Cleveland, OH 44106  
Phone: (216) 368-1175  
Email:  Henry.Koon@UHhospitals.org  
 
Patrick James  Flynn, M.D.  
Metro -Minnesota Community Clinical Oncology Program  
800 E 28th St, Suite 405  
Minneapolis, MN  55407  
Phone:  612-863-8585  
Fax:  612 -863-8586  
Email:  patrick.flynn@usoncology.com  
 
Karl Lewis, MD  
University of Colorado Cancer Center  
1665 Aurora Court  
Aurora, CO 80045  
Phone:  720 -848-0584  
Fax: 720 848 0526  
Email:  karl.lewis@ucdenver.edu   
 
Mohammed Milhem, MD  
University of Iowa Hospitals & Clinics  
200 Hawkins Drive, C32 GH  
  PhII-107, NCI# 8628  
  8.21.17 v 5 Iowa City, IA 52242  
Phone: 319 -356-2324  
Fax: 319 -353-8383  
Email:   mohammed -milhem@uiowa.edu   
 
Dr. Marc Ernstoff  
Cleveland Clinic Foundation  
Hematology and Medical Oncology  
9500 Euclid Avenue  
Taussig Cancer Institute Desk R35  
Cleveland, OH 44195  
Phone:  (216) 444 -0888  
Email:  ernstom@ccf.org   
 
City of Hope affiliates:  
Stephen Koehler , MD  
City of Hope Medical Group, Inc.  
209 Fair Oaks Avenue  
South Pasadena, CA  91030  
Phone: 626 -396-2900  
Fax: 626 -396-2912  
Email: Skhehler@cohmg.com   
 
Statistician:    Paul F rankel, Ph.D.  
City of Hope National Medical Center  
1500 E. Duarte Rd, Duarte, CA 91010 -3000  
Phone: 626 -359-8111 x65265  
Fax: 626 -471-7106  
E-mail: pfrankel@coh.org  
Participating Centers:  City of Hope National Medical Center, Duarte CA (COH)  
  and affiliates  
 USC/Norris Comprehensive Cancer Center, Los Angeles (USC)  
 University of California, Davis Cancer Center, Sacramento (UCD)  
  and affiliates  
 University of Pittsburgh, Pittsburgh, PA (UOP)  
 Penn State Milton S. Hers hey Medical Center (PSU)  
New York Medical College  
Karmanos Cancer Institute/ Wayne State University (WSU)  
Dartmouth Hitchcock Medical Center  
University of Virginia  
Indiana University Health  
Ohio State University  
Roswell Park Cancer Institute  
Northwestern M emorial Hospital  
Vanderbilt Univeristy  
Emory University  
  PhII-107, NCI# 8628  
  8.21.17 v 6 UH Case Medical Center  
University of Iowa Hospitals & Clinics  
Cleveland Clinic Foundation  
 
NCI Supplied Agent : Aflibercept (NSC 724770)  
 
Commercial Agent:  Aldesleukin (Interleukin -2) 
 
Protocol Version  Date:   June 14 , 2010    Intial Protocol  
  August 2 , 2010   Response to Consensus Review  
  August 18, 2010   Response to Follow Up Review  
  December 8, 2010  Amendment  
  December 20, 2010  Address recommendations, study  
        calendar  
  June 16, 2011    Updat e investigator on title page  
  July 18, 2011    Update investigator on title page  
  February 8, 2012   NCI RA CAEPR and risk profile  
  May 11, 2012    Amendment  
  December 17, 2012  Amendment  
  January 15, 2013   Amendment  
  September 19, 2013  Amendment  
  March  6, 2014   Amendment  – disapproved  
  March 18, 2014   Amendment  
  March 27, 2014   Amendment  
  April 22, 2014   Amendment  
  May 22, 2014    Amendment  
  January 8, 2015   Amendment  
  January 23, 2015   Amendment  – disapproved  
  February 3, 2015   Amendment  
  Augus t 10, 2015   Amendment  
  December 31, 2015  RRA  
  August 21, 2017   Amendment  
  PhII-107, NCI# 8628  
  8.21.17 v 7 SCHEMA  
This is a randomized phase II study of sequential biotherapy with aflibercept and high dose 
interleukin -2 (IL -2) versus high dose IL -2 alone in patients with advanced inoper able stage III or 
stage IV melanoma.  
 
Arm A: Combination of Aflibercept and IL -2. 
The planned treatment consists of 3 courses of combination aflibercept and high dose IL -2 
followed by maintenance aflibercept monotherapy. Response assessment will occur at the end of 
each course of  combination  therapy and patients without evidence of disease progression (RECIST 
v.1.1) or limiting toxicities will be offered additional courses of treatment (or maintenance 
aflibercept therapy) . 
 
Arm B: High dose IL -2 alone  
The planned treatment consists of 3 courses high dose IL -2. Response assessment will occur at the 
end of each course of therapy and patients without evidence of disease progression (RECIST v.1.1) 
or limiting toxicities will be offered additional courses of tre atment of high dose IL -2 for a 
maximum of 3 courses (6 cycles) . 
 
Arm A will be conducted in 2 phases: Combination and Aflibercept Monotherapy. The 
combination phase will consist of courses 1, 2 and 3 during which aflibercept  will be administered  
at 3mg/kg . For the Aflibercept Monotherapy phase, aflibercept will be administered  at 4 mg/kg .  
 
I. Combination Phase  (Arm A) : 
 
 
 
 
 
 
 
 Course 1  (Arm A)  
 Wk 
1 Wk 
2 Wk 
3 Wk 
4 Wk 
5 Wk 
6 Wk 
7 Wk 
8 Wk 
9 Wk 
10 
Aflibercept  
3 mg/kg IV X  X  X  X  X  
HD IL -2 
600,000 
U/kg/dose IV Q8 h 
x 5 days (max  14 
doses)    X  X      
Response 
Assessment           X 
  PhII-107, NCI# 8628  
  8.21.17 v 8  
 
II. Aflibercept Monotherapy /Maintenance  Phase  for Arm A : 
 
Following response assessment after course 3 of combination therapy and a fter resolution of 
all tox icities to ≤ grade 1 (CTCAE v.4), aflibercept monotherapy will be initiated to be 
administered at 4 mg/kg  IV on Day 1of each 14 -day cycle.  In this case, b lood pressure 
monitoring should be done weekly for the first 3 weeks of the maintenance phase to ensur e 
tolerance of the higher aflibercept dose.  However, if the aflibercept dose had to be reduced 
during the combination phase due to aflibercept -related toxicities, then that reduced dose will 
be used for maintenance therapy. No need for weekly monitoring of  blood pressure, if the 
reduced dose has already been demonstrated to be tolerable.   
 
Primary Objective: Test the hypothesis that combination biotherapy with aflibercept and HD IL -
2 will improve the progression -free survival compared to HD IL -2 alone.  
 
Secondary Objectives: (1) Evaluate the response rate (CR+PR) of aflibercept and HD IL -2 as 
assessed by RECIST criteria version 1.1 and compare to HD IL -2 alone.  (2) Evaluate the toxicities 
and tolerance of combination biotherapy with aflibercept and HD IL -2 and maintenance aflibercept 
alone in this patient population  and compare to HD -IL2 alone . (3) Test the hypotheses related to 
the laboratory correlative studies . (4) Evaluate the overall survival of patients treated on Arm A 
and B.  
 
The primary endpoint is progression -free survival.  The accrual goal is 105 patients , 70 on Arm A, 
and 35 on Arm B.  
 
Definitions:  
 
1. A cycle of IL -2: eligible patients receive high -dose IL -2 at 600,000 IU/kg IV every 8 hours 
for up to 14 doses. This constitutes one cycle of IL -2. 
2. A cycle of Aflibercept : eligible patients receive aflibercept at 3 mg/kg (combination 
phase) or 4 mg/kg (maintenance phase) IV every 2 weeks. This constitutes one cycle of 
aflibercept.  Course 2 (Arm A)  Course 3(Arm A)  
 Wk 
1 Wk 
2 Wk 
3 Wk 
4 Wk 
5 Wk 
6 Wk 
7 Wk 
8 Wk 
1 Wk 
2 Wk 
3 Wk 
4 Wk 
5 Wk 
6 Wk 
7 Wk 
8 
Aflibercept  
3 mg/kg IV   
X   
X   
X   
X   
X   
X   
X   
X  
HD IL -2 
600,000 
U/kg/dose IV 
Q8h x 5 days 
(max  14 
doses)   
 
X   
 
X   
   
   
 
X   
 
X   
    
Response 
Assessment          
X   
   
   
   
X 
  PhII-107, NCI# 8628  
  8.21.17 v 9 3. The combination phase  (Arm A) : during this phase, IL -2 and afliberce pt will be given 
concurrently. It consists of 3 courses of combination therapy.   
a. Each course consists of 2 cycles of IL -2 as follows: high -dose IL -2  at 600,000 
IU/kg is given IV every 8 hours for up to 14 doses (one cycle), followed by a rest 
period of  1-2 weeks and readmission for a second high dose IL -2 cycle  for up to 
14 doses (2nd cycle).  
b. In addition, aflibercept will be given concurrently at 3 mg/kg IV every 2 weeks , but 
in course 1 only aflibercept will start 2 weeks prior to IL -2. Therefore, cour se 1 will 
consist of 5 cycles of aflibercept, while courses 2 and 3 will consist of 4 cycles of 
aflibercept each.  
c. Based on the occurrence of treatment -related toxicities and requirements for dose 
adjustments or delays, a patient may or may not receive the  full planned treatment, 
but response assessment will continue to be carried out at the end of each course.  
4. The maintenance phase  (Arm A) : only aflibercept monotherapy will be given during this 
phase  for Arm A patients  at 4 mg/kg IV every 2 weeks. Response  assessment will be carried 
out every 12 weeks  (-/+1 week) for both arms (for arm A patients, approximately every 6 
cycles of aflibercept)  for the  first 2 years , then every 6 months ( -/+ 2 weeks) for years 3 -5, 
then yearly ( -/+ 4 weeks) afterwards .   
 
For arm B, patients will receive HD IL -2 alone following the institutional standard of care 
guidelines. Patients will receive a maximum of 3 courses (6 cycles; 1 course of IL_2 in arm B 
= 2 cycles of IL -2). Response assessment will be carried out at the end of  each course. In the 
absence of disease progression by RECIST v.1.1, patients will be offered additional courses of 
therapy for a maximum of 3 courses (6 cycles).  
  PhII-107, NCI# 8628  
  8.21.17 v 10 TABLE OF CONTENTS  
SCHEMA  ................................ ................................ ................................ ................................  7 
1. OBJECTIVES  ................................ ................................ ................................ ...............  11 
1.1. Primary Objectives ................................ ................................ ................................ .... 11 
1.2. Secondary Objectives ................................ ................................ ................................  12 
2. BACKGROUND  ................................ ................................ ................................ ..........  12 
2.1. Metastatic Melanoma  ................................ ................................ ................................  12 
2.2. Aflibercept (VEGF Trap, AVE0005)  ................................ ................................ ....... 12 
2.3. High Dose Interleukin -2 ................................ ................................ ...........................  19 
2.4. Rationale  ................................ ................................ ................................ ...................  21 
3. PATIENT SELECTION  ................................ ................................ ...............................  22 
3.1. Eligibility Criteria  ................................ ................................ ................................ ..... 22 
3.2. Exclusion Criteria  ................................ ................................ ................................ ..... 25 
3.3. Inclusion of Women and Minorities  ................................ ................................ .........  26 
4. REGISTRATION PROCEDURES  ................................ ................................ ..............  27 
4.1. General Guidelines ................................ ................................ ................................ .... 27 
4.2. Registration Process  ................................ ................................ ................................ .. 27 
5. TREATMENT PLAN  ................................ ................................ ................................ ... 28 
5.1. Overall Trea tment Plan  ................................ ................................ .............................  28 
5.2. Aflibercept Administration  ................................ ................................ .......................  30 
5.3. Aldesleukin (Interleukin -2) Administration  ................................ .............................  32 
5.4. General Concomitant Medication and Supportive Care Guidelines  .........................  34 
5.5. Duration of Therapy  ................................ ................................ ................................ .. 34 
5.6. Duration of Follow Up  ................................ ................................ ..............................  35 
6. DOSING DELAYS/DOSE MODIFICATIONS (Aflibercept)  ................................ ..... 35 
6.1. Management of Hypertension  ................................ ................................ ...................  36 
6.2. Proteinuria  ................................ ................................ ................................ .................  38 
6.3. Other Adverse Events  ................................ ................................ ...............................  38 
7. ADVERSE EVENTS:  LIST AND REPORTING REQUIREMENTS  .......................  39 
7.1. Comprehensive Adverse Events and Potential Risks Lists (CAEPRs)  ....................  39 
7.2. Adverse Event C haracteristics  ................................ ................................ ..................  49 
7.3. Expedited Adverse Event Reporting  ................................ ................................ .........  49 
7.4. Use the NCI protocol number and the protocol -specific patient I D assigned during 
trial registration on all reports.  Routine Adverse Event Reporting  ................................ ..... 50 
7.5. Secondary AML/MDS  ................................ ................................ ..............................  50 
8. PHARMACEUT ICAL INFORMATION  ................................ ................................ ..... 51 
8.1. CTEP -Supplied Investigational Agents  ................................ ................................ .... 51 
8.2. Commercial Agents  ................................ ................................ ................................ .. 53 
9. CORRELATIVE/SPECIAL STUDIES  ................................ ................................ ........  54 
9.1. Laboratory Correlative Studies  ................................ ................................ .................  54 
9.2. Anti-VEGF Trap Antibody  Testing  ................................ ................................ ..........  57 
10. STUDY CALENDAR  ................................ ................................ ..............................  60 
11. MEASUREMENT OF EFFECT ................................ ................................ ...............  63 
11.1. Antitumor Effect – Solid Tumors  ................................ ................................ .............  63 
12. DATA REPORTING / REGULATORY REQUIREMENTS  ................................ .. 67 
12.1.  Data Reporting  ................................ ................................ ................................ ..........  67 
  PhII-107, NCI# 8628  
  8.21.17 v 11 12.2.  CTEP Multicenter Guidelines  ................................ ................................ ...................  68 
12.3.  Cooperative Research and Development Agreement (CRADA)/Clinical Trials 
Agreement (CTA)  ................................ ................................ ................................ .................  69 
13. STATISTICAL CONSIDERATIONS ................................ ................................ ...... 71 
13.1.  Study Design/Endpoints ................................ ................................ ............................  71 
13.2.  Sample Size/Accrual Rate  ................................ ................................ .........................  71 
13.3.  Stratification Factors  ................................ ................................ ................................ . 71 
13.4.  Analysis of Secondary Endpoints  ................................ ................................ .............  71 
13.5.  Reporting and Exclusions  ................................ ................................ .........................  73 
14. CCCP POLICIES FOR MONITORING CONSORTIUM TRIALS  ........................  73 
15. REFERENCES  ................................ ................................ ................................ .........  76 
APPENDIX A – Performance Status Criteria  ................................ ................................ ....... 78 
APPENDIX B – CTEP Multicenter Guidelines  ................................ ................................ .... 79 
APPENDIX C – CCCP Registration Procedures for Phase II Trials  ................................ .... 81 
APPENDIX D – CCCP Specimen Submission Forms  ................................ .........................  82 
APPENDIX E – NYHA functional classification system  ................................ .....................  83 
APPENDIX F - Labeling Instructions for Serum Samples for Regeneron  (Anti -Aflibercept 
Antibody Testing)  ................................ ................................ ................................ ................  84 
APPENDIX G - COLLECTION OF SERUM SAMPLES for Regeneron (Anti -Aflibercept 
Antibody Testing)  ................................ ................................ ................................ ................  87 
APPENDIX H - Patient Blood Pressure Monitorin g Diary (for patients on Arm A receiving 
Aflibercept)  ................................ ................................ ................................ ..........................  88 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. OBJECTIVES  
1.1. Primary Objectives  
• Test the hypothesis that combination biotherapy with aflibercept and HD IL -2 will 
  PhII-107, NCI# 8628  
  8.21.17 v 12 improve the progression -free surviv al compared to HD IL -2 alone.  
 
1.2. Secondary Objectives  
• Evaluate the response rate (CR+PR) of aflibercept and HD IL -2 as assessed by 
RECIST criteria version 1.1 and compare to results of HD IL -2 alone.   
 
• Evaluate the toxicities and tolerance of combination b iotherapy with aflibercept and 
HD IL -2 and maintenance aflibercept alone in this patient population  and compare 
to HD IL -2 alone . 
 
• Test the hypotheses related to the laboratory correlative studies.  
 
• Evaluate the overall survival of patients treated with a flibercept and HD IL -2 and 
HD IL -2 alone.  
 
2. BACKGROUND  
2.1. Metastatic Melanoma  
Annually, about 8,000 patients are found to have metastatic melanoma presenting as a 
recurrence of an earlier primary melanoma, and this number closely approximates the 
annual number  of deaths from this disease  [1]. This statistic illustrates the lack of 
progress that has been made in the treatment of stage IV melanoma over the last several 
decades. Therapeutic approaches that have been studied in metastatic melanoma 
include chemotherapy, biochemotherapy, nonspecific immune adjuvants, cancer -
specific vaccines, cytokines, monoclonal antibodies, and specific immunostimulants  
[1]. Chemotherapy with single agent dacarbazine is the only US -FDA approved 
chemotherapy agent for metastatic melanoma. Immunological approaches have yielded 
the only new US -FDA appr oved agent for metastatic disease in 30 years, high -dose 
bolus interleukin -2 (IL -2), based on prolonged durable responses in some patients with 
metastatic melanoma  [2]. Participation in clinical trials is presently the best strategy to 
maximize therapeutic options and to access novel drugs in clinical development. Many 
novel therapeutic approaches are currently undergoing active clinical investigation and 
emerging da ta are promising from approaches targeting angiogenesis, or targeting 
groups of patients with specific activating mutations that are driving malignant 
proliferation such as the V600E BRAF mutation and  mutations and amplifications in 
the receptor tyrosine k inase c -kit.  This is in addition to immunotherapy with anti -
CTLA4 monoclonal antibodies.  Although promising, clinical benefits from current 
investigational agents appear to be of either limited duration and/or confined to small 
groups of patients.  There fore, there continues to be an urgent need for new therapeutic 
strategies building upon promising clinical activity data and solid preclinical rationale.  
  
2.2. Aflibercept (VEGF Trap , AVE0005)  
Aflibercept is a recombinant fusion protein consisting of human vas cular endothelial 
growth  factor (VEGF) receptor extracellular domains fused to the Fc portion of human 
  PhII-107, NCI# 8628  
  8.21.17 v 13 immunoglobulin  G1 (IgG1). Aflibercept contains portions of the extracellular domains 
of 2 different vascular  endothelial growth factor receptors (VEGFRs) : VEGFR1 (also 
known as Flt -1) and VEGFR2  (also known as KDR or Flk -1). Aflibercept drug product 
is formulated as a sterile liquid for  intravenous (IV) administration [3]. 
 
Aflibercept binds VEGF in the picomolar (pmol/L) range, and also binds placental 
growth factor  (PlGF), although with  lower affinity. The affinity constants (Kd) for 
binding to 2 human isoforms of VEGF, VEGF165 and VEGF121, are 0.50 pmol/L and 
0.36 pmol/L, respectively. The Kd for human PlGF2 is 39 pmol/L. The binding of 
aflibercept to its ligands in vivo is expected to block tumor angiogenesis and vascular 
permeability.  
 
Aflibercept has been found to be active with a broad pharmacological index against 
early and  advanced stage disease in a variety of preclinical solid tumor models 
including sarcomas, and  ovarian, prostat e, mammary, colon, and gastric carcinomas 
when used as a single agent or in  combination with cytotoxic agents. In mouse models 
of ascites formation with ovarian and renal  cell carcinoma, aflibercept inhibited ascites 
formation and reduced tumor burden.  
 
Doses have been administered up to 800 μg/kg subcutaneously (SC) twice weekly, 7 
mg/kg IV  every 2 weeks, and 9 mg/kg IV every 3 weeks. The most common adverse 
events reported for aflibercept monotherapy include: hypertension, proteinuria, 
epistaxis, dysphoni a, pain (including abdominal pain and back pain), asthenia/fatigue, 
nausea, vomiting, headache, constipation, myalgia, arthralgia, dyspnea, decreased 
appetite, and diarrhea.  
 
Target pharmacological exposure has been reached at doses ≥2 mg/kg IV given every  
2 weeks.  Free aflibercept levels have remained in excess of bound aflibercept levels 
throughout the dosing  intervals at this, or higher, doses. Objective tumor responses and 
prolonged (>1year) disease  stabilization have been reported at dose levels ≥800 μ g/kg 
SC and ≥1 mg/kg IV with aflibercept  monotherapy and with aflibercept administered 
in combination with cytotoxic chemotherapy.  Phase 1 studies, as both single agent and 
combination chemotherapy, are ongoing. Phase 2  studies of aflibercept, either alone  or 
in combination with standard cytotoxic agents, are ongoing  in a variety of oncologic 
indications. Phase 3 combination studies are ongoing in the following  indications: lung 
cancer, colorectal cancer, pancreatic cancer, and prostate cancer  [3]. 
 
2.2.1.  Animal Toxicology  
 
The toxicity profile  of aflibercept was evaluated in monkeys. The main compound -
related  microscopic findings were in the bone, nasal cavity, kidney, ovary, and 
adrenal gland. In the  bone, aflibercept -induced effects consisted mainly of 
thickening of the growth plate and  osteo cartilaginous exostoses observed on the 
axial and appendicular skeleton that correlated with  hunched posture at clinical 
examination. In the nasal cavities, degeneration/regeneration of the  respiratory and 
olfactory epithelium, and atrophy/loss of nasal se ptum and/or turbinates was often 
  PhII-107, NCI# 8628  
  8.21.17 v 14 associated with hemorrhage and suppurative exudate. Histopathologic findings in 
the kidneys (increased glomerular mesangial matrix) were associated in a few 
animals with decreased serum total protein and albumin levels and increased serum 
blood urea nitrogen (BUN) and urine protein and/or microalbumin levels. In the 
ovaries, the decreased number of maturing follicles, granulose cells, and/or theca 
cells was associated with an overall inhibition of the female reproductive fun ction. 
In the adrenals, a decreased vacuolation of adrenal zona fasciculata cells with 
cytoplasmic eosinophilia was observed. In addition, focal vascular 
proliferation/degeneration was noted in a range of organs, including in particular 
the digestive syste m, urinary bladder, heart, and brain of a few monkeys. In 
addition, increased liver enzyme levels were noted in a few monkeys with portal 
inflammation and necrosis. Aflibercept administration also resulted in a decrease 
in sperm motility and increased inci dence of abnormal spermatozoa morphology. 
Most aflibercept -related findings were noted from the lowest doses tested (1.5 to 3 
mg/kg/administration). With the exception of osteocartilaginous exostoses and 
nasal cavity findings, aflibercept -related findings were reversible within 5 months 
after treatment cessation. In sexually immature monkeys treated for 3 months, the 
main compound -related findings were comparable to those in sexually mature 
monkeys.  
 
Aflibercept was shown to induce a moderately delay in wou nd repair and healing 
from 0.3 mg/kg/administration after IV administration in rabbits. When 
administered IV to pregnant rabbits (as a 30 minute infusion once daily, on 
gestation Days 6, 9, 12, 15, and 18 - a total of 5 administrations) aflibercept induced  
minimal to moderate maternal toxicity, abortion, and embryolethality at 60 
mg/kg/administration. External, visceral, and/or skeletal malformations were 
observed in fetuses from pregnant rabbits treated from 3 mg/kg/administration 
(approximately 1.3 times the exposure in patients treated at the recommended 
human dose).  
 
2.2.2.  Mechanism of Action  
 
VEGF is a molecule produced by tissues to stimulate angiogenesis. VEGF 
production by tumors is required for vascularization and thus, the survival and 
growth of tumors. VEGF protein that is not internalized through its VEGF receptor 
mediated signaling reaches the circulation where it is cleared rapidly. The VEGF 
Trap, a long -acting inhibitor of VEGF signaling, potently binds and  inactivates 
VEGF, thus blocking tumor angio genesis and growth in both animal models of 
cancer and in humans with a variety of cancers.  
 
2.2.3.  Pharmacokinetics  
 
Free aflibercept is cleared by 2 mechanisms in humans: (1) a fast clearance by 
binding systemic  VEGF to form bound aflibercept, and (2) a slower pathway where 
the free aflibercept is  eliminated by other biological mechanisms, perhaps 
analogous to the clearance of free antibodies  (proteins). The results in humans are 
  PhII-107, NCI# 8628  
  8.21.17 v 15 similar to observations in animal studies.  
 
The clinical kinetics of aflibercept we re characterized by a low volume of 
distribution  approaching blood volume and a low clearance decreasing with dose 
in the dose range 0.3 to  
2 mg/kg, then stable at higher doses.  
 
Target pharmacological exposure has been reached at 0.8 mg/kg SC given weekly  
or ≥2 mg/kg IV doses given every 2 weeks. Free aflibercept levels have remained 
in excess of bound aflibercept levels throughout the dosing intervals at these doses.  
 
Following IV administration, the pharmacokinetics of free aflibercept were not 
linear follow ing administration of <2 mg/kg doses, but became linear between the 
2 and 7 mg/kg dose levels. The  
pharmacokinetics of free aflibercept were characterized by high fluctuation and 
essentially no  accumulation when given every 2 weeks. The concentrations of 
bound aflibercept increased  between the 0.3 and 2 mg/kg dose levels, and then 
plateaued between the 2 and 7 mg/kg dose  levels, suggesting that free aflibercept 
was available in sufficient amount to bind all endogenous  VEGF in this higher dose 
range.  
 
Free a nd bound aflibercept concentrations determined in combination studies are 
in the same  order of magnitude of those observed in the monotherapy study 
TED6115, suggesting that  cytotoxic combinations (FOLFOX 4, irinotecan, 5 -FU, 
docetaxel, and gemcitabine) hav e no influence on the PK of aflibercept. Anti -
aflibercept antibodies have been reported using ELISA  methods. These findings are 
not unexpected, as aflibercept is a recombinant protein product. The  
immunogenicity testing with present methods showed that les s than 1% of patients 
evaluated  developed anti -aflibercept antibodies. Further assay development is 
ongoing and the implications  and understanding of anti -aflibercept antibodies is 
under evaluation.  
 
2.2.3.1.  Pharmacokinetic/Pharmacodynamic Relationships  
 
Preclini cally, circulating levels of VEGF Trap complex appear to be good 
biomarkers of efficacy. VEGF is normally cleared rapidly and does not 
accumulate, but binding to VEGF Trap creates an inactive VEGF :VEGF 
Trap complex with a longer half -life that accumulates to detectable levels. 
Because of the high affinity of VEGF Trap for VEGF, free VEGF Trap is 
rapidly converted to the bound form unless VEGF Trap levels exceed the 
amount of VEGF  synthesized over the dosing interval. At high doses of 
VEGF Trap, essentially all VEGF is trapped, VEGF :VEGF Trap complex 
formation is saturated, and free VEGF Trap accumulates. Antitumor 
efficacy in animal xenograft models was observed at VEGF Trap doses that 
resulted in saturation of steady -state VEGF :VEGF Trap complex (bound 
VEGF  Trap) plasma levels and an excess of free VEGF Trap over the 
  PhII-107, NCI# 8628  
  8.21.17 v 16 complex concentrations, as shown in Figure 2 of the  Investigator’s 
Brochure  [3]. 
 
2.2.4.  Clinical Experience  
 
To date, aflibercept has been administered to 76 healthy subjects and approximately 
2000 patients with advanced solid malign ancies in clinical oncology trials. In 
company -sponsored trials, doses have been administered up to 800 μg/kg twice 
weekly SC and 7 mg/kg IV every 2 weeks, and 9 mg/kg IV every 3 weeks across 
13 Phase 1 clinical trials (11 oncology trials), four Phase 2 si ngle agent, two Phase 
2 combination trials, and four Phase 3 combination trials. Details of Phase 1 trials 
in healthy subjects are presented in Table 36 of IDB. Details of the company 
sponsored clinical oncology trials are presented in Table 37 of IDB; SAE s in these 
trials are summarized in Table 39 of ID, Table 40 of IDB, Table 41 of IDB, and 
Table 42 of ID . 
 
2.2.4.1.  Efficacy  
 
In the single agent Phase 1 study of SC aflibercept, 2 patients, 1 with heavily 
pretreated  bronchoalveolar carcinoma and another with medu llary thyroid 
cancer, improved either  subjectively and/or radiologically at a dose of 800 
μg/kg with prolonged disease stabilization of  over 2 years.  
 
In the Phase 1 studies of IV single agent aflibercept (TED6115 and 
TED6116), 3 patients have  had RECIST -defined partial tumor responses: 1 
patient with metastatic malignant thymoma  treated at the 3 mg/kg dose 
level, and 2 patients with ovarian cancer treated at the 7 mg/kg dose  level. 
Two patients with renal cell cancer, treated at the 1 mg/kg and 2 mg/kg dos e 
levels,  respectively, have had prolonged (exceeding one year) stable disease 
(SD).  
 
Single agent Phase 2 studies in previously treated patients (2 or more lines 
of chemotherapy  treatment) have evaluated aflibercept administered IV 
every 2 weeks in ovaria n and lung cancer  (ARD6122, ARD6123) with 
response rate as the primary endpoint. In ARD6123, a single agent,  single 
arm study of aflibercept at 4 mg/kg in advanced, heavily pretreated non -
squamous nonsmall cell lung cancer (NSCLC), an Investigator -reported  
overall response rate (ORR) of 2% was observed, along with a median 
progression free survival (PFS) of approximately 12 weeks, and stable 
disease (SD) for ≥60 days of approximately 30%. The median overall 
survival (OS) was approximately 6 months. In ARD6122, a randomized, 
double -blind study of aflibercept at  2 mg/kg or 4 mg/kg in advanced ovarian 
cancer, the Investigator -reported ORR was 3.8% in the  2 mg/kg arm and 
7.3% in the 4 mg/kg arm; the median PFS in both arms was approximately  
18 weeks, and SD for ≥60 days of approximately 45% and 37% in the 2 
mg/kg and 4 mg/kg arms, respectively. The median OS was approximately 
  PhII-107, NCI# 8628  
  8.21.17 v 17 55 weeks in the 2 mg/kg arm and 50 weeks in the 4 mg/kg arm.  
 
Additionally, single agent Phase 2 studies have explored the efficacy of 
aflibercept in prolonging  the time to repeat paracentesis in advanced ovarian 
cancer patients with symptomatic malignant  ascites (SMA). Study 
ARD 6772 explored 4 mg/kg IV every 2 weeks, and showed at least a  
doubling of the primary endpoint (time to repeat paracentesis compared to 
baseline) for 62% of  the patients. Study EFC6125, a randomized, double 
blind study of aflibercept 4 mg/kg IV every  2 wee ks versus placebo, in a 
similar patient population, is still ongoing.  
 
In the combination Phase 1 studies, radiological tumor responses per 
RECIST criteria have been  observed across different tumor types and 
aflibercept doses.  
 
2.2.4.2.  Phase II monotherapy study in advanced melanoma  
 
A phase II study of aflibercept in patients with inoperable stage III or IV 
melanoma who had received no prior chemotherapy or hormonal therapy 
has recently completed accrual. A 2 -stage design was adopted focusing 
upon response rate ( RECIST) and 4 -month PFS rate. First stage accrual of 
21 patients was specified, and accrual continued to a total of  41 patients 
due to an adequate 4 month PFSR. Aflibercept was given at 4 mg/kg IV 
every 2 weeks. Response was assessed every 8 weeks. Forty one patients 
(26 male, 15 female), age 23 -83 (median 57) have been enrolled. All had 
AJCC stage IV melanoma (2N3, 3M1a, 8M1b, 28M1c). Karnofsky PS: 100 
(19), 90 (14) or 80 (8). Ten patients had primary ocular melanoma, 28 
cutaneous and 3 unknown primary si te. A median of 4 cycles have been 
administered (range 1 -23). Grade 3/4 toxicities included cerebral ischemia 
(1 patient; 2%), confusion (1; 2%), thrombocytopenia (1; 2%), hypertension 
(8; 20%), hypotension (1; 2%), left ventricular diastolic dysfunction ( 1; 
2%), fatigue (1; 2%), proteinuria (4; 10%), extraocular muscle paresis (1; 
2%), renal failure (1; 2%), back pain (1; 2%), headache (1; 2%), 
osteonecrosis of mandibular bone in a patient with a history of external 
beam radiation therapy. Overall, one pat ient (cutaneous, M1c) had a 
confirmed partial response (potential CR; duration of PFS = 293+ days) . 
Twenty patients have had stable disease (10 ongoing, 10 have progressed). 
Four patients were taken off study prior to response evaluation for toxicity 
(3) o r treatment refusal (1). One patient is currently disease free who was 
not evaluable for response (previous surgery and radiofrequency ablation 
of measurable disease site). Thirteen patients had progression at first 
assessment point. Thus far 16 patients ( excluding the non -evaluable NED 
patient) have had at least 4 months of PFS. Eight additional patients are still 
on treatment, but have not reached the 4 month PFS milestone.  
 
These results have lead the investigators to conclude that aflibercept  has a 
  PhII-107, NCI# 8628  
  8.21.17 v 18 prom ising clinical activity in metastatic melanoma of cutaneous or ocular 
origin. The final conclusions on the activity of aflibercept as single agent in 
metastatic melanoma require additional follow up (4 months after the last 
patient has started treatment). These data however, provide strong rationale 
for moving forward with further development of aflibercept in combination 
therapy with agents that are known to be active in melanoma [4]. 
 
2.2.5.  Safety Considerations  
 
Phase 1, 2, and 3 oncology studies are ongoing, as both single agent and 
combination trials.  
 
In healthy subjects, administration of a single dose, or up to 2 doses of 1, 2, or 4 
mg/kg of  aflibercept by IV infusion, or 2 mg/kg by SC route, was considered safe 
and showed an acceptable tolerability. The most frequently reported treatment 
emergent n on-serious AEs included headache, dysphonia, epistaxis, acneiform 
dermatitis, nasopharyngitis, arthralgia, diarrhea, ALT increase, and 
nausea/dyspepsia. No serious adverse events (SAEs) were reported in healthy 
subjects.  
 
All grade treatment emergent adver se events (TEAEs) commonly reported across 
single agent  oncology trials, regardless of relationship to study drug, include 
hypertension, proteinuria,  epistaxis, dysphonia, pain (including abdominal pain, 
musculoskeletal pain, and back pain),  asthenia/fatig ue, constipation, nausea, 
vomiting, diarrhea, dizziness, headache, cough, dyspnea,  decreased appetite, 
peripheral edema, and pyrexia. Serious and less commonly reported events  include 
thrombotic microangiopathy, cardiac failure, gastrointestinal hemorrhage , 
intestinal  perforation, hemoptysis, tracheoesophageal fistula, enterocutaneous 
fistula, reversible posterior  leukoencephalopathy syndrome (RPLS), intracerebral 
hemorrhage, cerebral ischemia, deep vein  thrombosis and pulmonary embolism. 
Although these AEs  may be drug related, an association  with the underlying disease 
and the heavily pretreated patient population studied cannot be ruled  out at this 
stage of development.  
 
All grade TEAEs commonly reported across trials exploring aflibercept in 
combination w ith other anticancer drugs are similar to the single agent drug safety 
profile but also reflect common  toxicities associated with the drugs used in these 
combination regimens. Some anticancer drugs  being explored in Phase 1 
combination studies include: doc etaxel, gemcitabine, erlotinib,  irinotecan, 
oxaliplatin, cisplatin, and fluorouracil. Adverse events commonly reported in the  
combination trials include hypertension, proteinuria, epistaxis, dysphonia, pain 
(including  abdominal pain, musculoskeletal pain, and back pain), asthenia/fatigue, 
nausea, vomiting,  headache, constipation, dyspnea, decreased appetite, diarrhea, 
and also include neuropathy,  stomatitis and mucosal inflammation, electrolyte 
changes (including hypomagnesemia), and  alopecia. Hematological  abnormalities 
commonly reported in the combination trials include  neutropenia, anemia, and 
  PhII-107, NCI# 8628  
  8.21.17 v 19 thrombocytopenia.  
 
For  more details on AEs associated with Aflibercept, please refer to the current 
version of the IDB [3]. 
 
2.3. High Dose Interleukin -2 
IL-2  plays a central role in immune regulation  as it affects the survival of key cells of 
the immune system that are responsible for the antitumor cytotoxicity of T -
lymphocytes and natural -killer (NK) cells, and it has a cofactor role in the activation of 
B cells and macrophages [5]. The administration of IL -2 at high bolus IV doses once 
every eight hours was a regimen developed by the National Cancer Institute (NCI) 
based on animal models indicating that antitum or activity with this agent was dose -
dependent [6][6][6][6][6][7].  Initial studies with HDB IL -2 utilized doses of 600,000 -
720,000 units/kg every 8 hours from days 1 -5 (cycle 1) and days 15 -19 (cycle 2) with 
a maximum of 14 doses per c ycle or 28 doses per course (1 course = 2 cycles).  
Responding or stable patients were offered a second course of therapy 8 -12 weeks later. 
IL-2 was administered either as a single agent or in combination with immunologically 
active cells, so -called adopti ve immunotherapy. The latter technique utilized two types 
of immune cells: the lymphokine - activated -killer (LAK) cells and the tumor 
infiltrating lymphocytes (TIL).  
 
Eight clinical trials conducted between 1985 and 1993 and using the HDB IL -2 regimen 
described above, with or without LAK cells, were reviewed in a retrospective analysis. 
These trials had an enrollment of 270 patients with advanced metastatic melanoma [7-
9][7-9][7-9][7-9][7-9][8-10]. In those studie s that involved the concurrent 
administration of LAK cells, these cells were obtained using leukapheresis from 
patients during the rebound lymphocytosis that occurs following treatment and 
cessation of bolus IL -2 (days 8 to 12). LAK cells were then culture d in IL -2 for 3 to 4 
days. These generated LAK cells were reinfused with IL -2 during the second cycle of 
IL-2 administration. The retrospective analysis of these trials with a follow -up through 
December 1998 along with a more recent update demonstrated an objective response 
rate of 16% with durable responses in 4% of patients [2, 10][2, 10][2, 10][2, 10][2, 
10][3, 11] . The median response duration was 8.9 months (range 4 to 106+ months). 
Twenty eight percent of the  responding patients, including 59% of those patients who 
had achieved a complete response, have remained progression free at a median follow -
up of 62 months. Furthermore, no patient who had responses longer than 30 months 
has relapsed, suggesting the poss ibility that these patients may be “cured”. The 
frequency of the responses was similar in patients with visceral metastases and/or large 
tumor burdens, but the responses were less in patients with poor performance status or 
those who had received prior sys temic therapy. Based on these data, HDB IL -2 received 
approval by the US -FDA for the treatment of metastatic melanoma 
[11][11][11][11][11][12]. In addition to being logistically challenging, randomized 
studies have not shown superiority for IL -2 administered with LAK cells versus therapy 
with HD IL -2 alone [12][12][12][12][12][13]. Furthermore, a randomized phase III 
trial of CD8+ TIL given in combination with rIL -2 in metastatic renal cell carcinoma 
has been negative [13][13][13][13][13][14]. 
  PhII-107, NCI# 8628  
  8.21.17 v 20  
2.3.1.  Baseline Serum VEGF as a Predictor for Non -Response to HD IL -2 
 
Sabatino et al . have reported the results of proteomic analysis of the serum of 
patients (predominantly with metastatic melanoma; N=100, including 48 with 
melanoma and 11 with RCCA) who were treated with high -dose IL -2, using a 
customized, multiplex antibody targeted pr otein array platform to survey 
expression of soluble factors associated with tumor immunobiology [14].  Soluble 
factors associated with clinical responses were analyzed using a multivariate 
permutation test and survival outcomes were determined using Kaplan -Meier and 
log-rank tests. The customized Pierce SearchLight Proteome ArraysR, (Boston, 
MA) measured 16 proteins per well in standard 96 well plates spotted wi th different 
monoclonal antibodies. Sandwich ELISA was utilized to generate 
chemiluminescence signals for calculation of the levels of each analyte. Sixty 
patients were enrolled in this study. One patient did not complete staging scans and 
could not be inc luded in response determination leaving 59 patients for complete 
analysis. Nineteen patients exhibited an objective response to IL -2 therapy; 18 of 
48 melanoma patients (5 complete and 13 partial) and 1 of 11 RCC patients (1 
partial) responded.  
 
A training  set of 10 patients identified 68 of 110 analytes as potentially relevant 
and an independent validation set of 49 patients was then analyzed.  Vascular 
endothelial growth factor (VEGF) and fibronectin were identified as independent 
predictors of non -respon se to HD IL -2. In particular, high levels of these proteins 
correlated with lack of clinical response and decreased overall survival.  
Combining training and validation analyses identified only VEGF as a predictor of 
response to IL -2 therapy, although fibr onectin maintained statistical significance 
after combining the data sets suggesting a potential role as an independent 
predictive biomarker. Patients with serum VEGF levels greater than 125 pg/ml or 
fibronectin levels greater than 8 x 106 pg/ml did not re spond to IL -2 therapy and 
elevated levels of these proteins were also associated with a significantly worse 
overall survival. The VEGF family plays a critical role in mediating angiogenesis, 
lymphangiogenesis, and vasculogenesis and has an impact on host i nnate and 
adaptive immunity [15, 16].  The role of excess VEGF on tumor angiogenesis is 
well documented and recently high circulating serum levels of VEGF were 
associated with poor prognosis in patients with metastatic melanoma [17]. VEGF 
has been shown to block maturation of dendritic cells and inhibit effective priming 
of T cell responses [18, 19]. These data support an important role for VEGF in the 
progression of cancer and evasion of anti -tumor immunity. A therapeutic strategy 
designed to deplete high serum VEGF levels prior to HD IL -2 administration may 
reverse the negative impact of h igh serum VEGF on dendritic cell maturation and 
T cell priming allowing more effective antitumor T cell cytotoxicity induced by 
HD IL -2.  
 
2.3.2.  Studies Testing Bevacizumab in Combination with HD IL -2 
 
  PhII-107, NCI# 8628  
  8.21.17 v 21 The safety of the combination of VEGF Trap and High dose IL -2 can be expected 
based on studies involving bevacizumab and IL -2. These include an ongoing phase 
II study of bevacizumab and HD IL -2 in patients with metastatic renal cell 
carcinoma (A Cytokine Working Group Study) .  In this study , patients  receive 
bevaci zumab IV over 30 -90 minutes on days -13, 1, 15, 29, 43, 57, and 71 during 
course 1 and on days 1, 15, 29, 43, 57, and 71 during courses 2 and 3. Patients also 
receive high -dose interleukin -2 every 8 hours on days 1 -5 and 15 -19. Treatment is 
repeated every 84 days for up to 3 courses in the absence of disease progression or 
unacceptable toxicity. Results of the first 15 of a planned 60 patients were reported 
in the ASCO 2007 Annual Meeting (Ernstoff et al.; Abstract 15524) demonstrated 
that HD IL -2 and bevac izumab can be given safely. This study has been updated 
for ASCO 2010 revealing a consistent safety profile ( Dandamudi UB, et al. 
Abstract #4530 ).  Another study presented in ASCO 2007 (Gracia et al.; Abstract 
5103), is a phase II trial of low -dose IL -2 (250,000 U/kg/d SC D1 -5 during week 1 
and 125,000 U/kg/d SC D1 -5 during weeks 2 -6, followed by a 2 week break) and 
bevacizumab (10mg/kg was administered IV every 2 weeks starting on day -14) in 
patients with metastatic renal cell carcinoma.  
 
2.4. Rationale  
The VE GF family plays a critical role in mediating angiogenesis, lymphangiogenesis, 
and vasculogenesis and has an impact on host innate and adaptive immunity [15, 16].  
The role of excess VEGF on tumor angiogenesis is well documented and recently high 
circulating serum levels of VEGF were associated with poor prognosis in patients with 
metastatic melanoma [17]. VEGF has been shown to block maturation of dendritic cells 
and inhibit effective priming of T cell responses [18, 19]. These data support an 
important role for VEGF in the progression of cancer and evasion of anti -tumor 
immunity. In additio n, recent studies have identified baseline serum VEGF as  a marker 
of immune resistance that is predictive for non -response to HD IL -2 [14]. A therapeutic 
strate gy designed to deplete high serum VEGF levels prior to HD IL -2 administration 
may reverse the negative impact of high serum VEGF on dendritic cell maturation and 
T cell priming allowing more effective antitumor T cell cytotoxicity induced by HD 
IL-2. in ad dition, our data with a flibercept as monotherapy  has shown promising 
clinical activity in advanced metastatic melanoma with an acceptable safety profile [4].  
 
We hypothesize that sequential biotherapy with aflibercept, as a high -affinity soluble 
VEGF receptor and potent angiogenesi s inhibitor, and HD IL -2 will lead to improved 
anti-tumor immunity compared to HD IL -2 alone. This should translate into improved 
anti-tumor clinical efficacy compared to either single agent.  
 
2.4.1.  Rationale for the doses selected in the combination and monther apy phases  
 
The study will be conducted in 2 phases  for arm A patients : Combination and 
Aflibercept Monotherapy. The combination phase will consist of courses 1, 2 and 
3 during which aflibercept will be administered at 3mg/kg. For the Aflibercept 
Monothera py Phase aflibercept will be administered at 4 mg/kg.  
 
  PhII-107, NCI# 8628  
  8.21.17 v 22 Our primary hypothesis is that the reduction or depletion of high serum VEGF 
levels prior to HD IL -2 administration would reverse immune resistance and the 
negative impact of high serum VEGF on dendrit ic cell maturation and T cell 
priming allowing more effective antitumor T cell cytotoxicity induced by HD IL -
2. It will ultimately lead to a significant improvement in clinical outcome.   
 
For aflibercept, target pharmacological exposure has been reached at  doses ≥2 
mg/kg IV given every 2 weeks. Free aflibercept levels have remained in excess of 
bound aflibercept levels throughout the dosing intervals at this, or higher doses. In 
addition, the concentrations of bound aflibercept were to increase between the 0.3 
and 2 mg/kg dose levels, and then plateau between the 2 and 7 mg/kg dose levels, 
suggesting that free aflibercept was available in sufficient amount to bind all 
endogenous VEGF in this higher dose range.  
 
Our experience with Aflibercept monotherapy at 4 mg/kg in a phas e II study 
conducted in melanoma has shown that approximately 16 (out of 41) patients that 
had an aflibercept  dose delay due to toxicity in the first 6 months of therapy. There 
were also 18 patients (of the 41) who had grade 3 or 4 toxici ty attributed (possibly, 
probable or definite) to VEGF -trap. All patients who had grade 3 -4 had their first 
grade 3 -4 within the first 6 months. Therefore, we expect that at 4 mg/kg a 
significant group of patients may have the HD IL -2 treatment delayed in the 
combination phase.  
 
3. PATIENT SELECTION  
3.1. Eligibility Criteria  
3.1.1.  Patients must have histologically or cytologically confirmed metastatic melanoma  
(includes AJCC stage IV or advanced/inoperable stage III. Also includes patients 
with a history of lower stage m elanoma and subsequent recurrent metastatic disease 
that is either locally/regionally advanced/inoperable disease or distant metastases).   
 
3.1.2.  Patients must have measurable disease, defined as at least one lesion that can be 
accurately measured in at least o ne dimension (longest diameter to be recorded) as 
>10 mm wit h CT scan  or clinically (must be measurable with calipers) according 
to RECIST version 1.1 [20].  See S ection 10 for the evaluation of measurable 
disease.  
 
3.1.3.  Patients must be free of brain metastasis by contrast -enhanced CT/MRI scans 
within 4 weeks prior to enrollment.  If known to have prior brain metastases, must 
not have evidence of active brain diseas e after definitive therapy (surgery, radiation 
therapy or stereotactic radiosurgery) on two successive MRI evaluations at least 3 
months apart (one of which is  4 weeks prior to starting the study drugs).  
 
3.1.4.  A patient may be treatment naïve. However, up to two prior regimens for metastatic 
melanoma are allowed. Prior adjuvant IFN -α is allowed. No prior therapy with 
bevacizumab, aflibercept or interleukin -2 (IL -2).  
  PhII-107, NCI# 8628  
  8.21.17 v 23  
Patients must not have received systemic therapy or radiotherapy within the 
preceding 4 weeks . Patients must have recovered from adverse events due to agents 
administered more than 4 weeks earlier.  
 
Patients must be at least 4 weeks from major surgery and have fully reco vered from 
any effects of surgery, and be  free of significant detectable infec tion. 
 
For patients who have received prior anti -CTLA4 monoclonal antibody therapy 
(ipilimumab or tremelimumab), there is a risk of bowel perforation with IL -2 
therapy. Therefore, for these patients if they have a history of colitis or diarrhea 
during anti -CTLA4 monoclonal antibody therapy , they should have a formal 
evaluation by a gastroenterologist and a colonoscopy should be considered to 
demonstrate  the absence of active bowel inflammation before initiating IL -2 
therapy on this protocol.    
3.1.5.  Age > 16 years.   
 
Because VEGF Trap interferes with growth plate maturation in animals, this agent 
may be inappropriate for use in patients <16 years of age. For this reason and 
because no dosing or adverse event data are available on the use of VEGF Trap in 
children,  patients <16 years of age are excluded from this study but may be eligible 
for future pediatric single -agent trials, if applicable.  
 
3.1.6.  Life expectancy of greater than 3 months in the opinion of the investigator.  
 
3.1.7.  ECOG performance status 0 or 1  (Karnofsky > 70%; see Appendix A).  
 
3.1.8.  Patients must have normal organ and marrow function as defined below:  
 
- leukocytes       >3,000/mc L 
- absolute neutrophil count   >1,500/mc L 
- platelets       >100,000/mc L 
- total bilirubin      within 1.5 x institutional upper limit of 
normal  
- AST(SGOT)/ALT(SGPT)  <2.5 X institutional upper limit of normal  
- creatinine       within 1.5 x institutional upper limit of 
normal  
OR 
- creatinine clearance    >60 mL/min/1.73 m2 for patients with 
creatinine levels above institutional normal  
 
3.1.9.  Urine  protein should be screened by urinalysis for Urine Protein Creatinine  Ratio 
(UPCR). For UPCR > 1, a 24 -hour urine protein should be obtained  and the level 
should be <500 mg.   
 
3.1.10.  Patients on full -dose anticoagulants (e.g., warfarin) with PT INR >1.5 are elig ible 
  PhII-107, NCI# 8628  
  8.21.17 v 24 provided that both of the following criteria are met:  
 
a) The patient has an in -range INR (usually between 2 and 3) on a stable 
dose of oral anticoagulant or on a stable dose of low molecular weight 
heparin.  
 
b) The patient has no active bleeding or p athological condition that carries 
a high risk of bleeding (e.g., tumor involving major vessels or known 
varices).  
  
3.1.11.  Pulmonary:  FEV1 > 2.0 liters or > 75% of predicted for height and age.  (PFTs are 
required for patients over 50 years old or with signific ant pulmonary or smoking 
history).   
 
3.1.12.  Cardiac:  No evidence of congestive heart failure, symptoms of coronary artery 
disease, m yocardial infarction less than 6 months prior to entry, serious cardiac 
arrhythmias, or unstable angina.  
 
Patients who are over 4 0 years old or have had previous myoc ardial infarction 
greater than 6 months prior to study entry or have significant cardiac family history 
(CAD or serious arrhythmias) will be required to have a negative or low probability 
cardiac stress test ( for exampl e, thallium stress test, stress MUGA , stress echo  or 
exercise stress test) for cardiac ischemia within 8 weeks prior to registration.  
An echocardiogram should be performed at baseline in all patients. Ejection 
fraction (EF) from baseline echocardiogram mus t be within the institutional limits 
of normal as determined by the reading cardiologist. If the baseline cardiac stress 
test incorporates an echocardiogram, then this will not need to be done again at 
baseline.  
 
3.1.13.  CNS:  No history of cerebrovascular accide nt or transient ischemic attacks     within 
the past 6 months .  
 
3.1.14.  Although clinical data are lacking on the immediate or long -term effects o f 
aflibercept on the developing human fetus, the agent is teratogenic and  negatively 
affects fetal development in anim al models. For this reason and  because 
antiangiogenic agents as well as other therapeutic agents used in this  trial are known 
to be teratogenic, women of child -bearing potential and men  must agree to use 
adequate contraception (hormonal or barrier method o f birth  control; abstinence) 
prior to study entry, for the duration of study participation, and for at least 6 months 
after completion of stud y therapy . Should a woman become pregnant or suspect she 
is pregnant while  participating  in this study, she should  inform her treating 
physician immediately.  
 
Women should not be lactating and, if of childbearing age, should have a negative 
pregnancy test (b-HCG test; serum or urine, minimum sensitivity 25 IU/L or 
equivalent units of b -HCG) within two week of registra tion in the study.  
  PhII-107, NCI# 8628  
  8.21.17 v 25  
3.1.15.  Ability to understand and the willingness to sign a written informed consent 
document.  
 
3.2. Exclusion Criteria  
3.2.1.  Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for 
nitrosoureas or mitomycin C) prior to entering the  study or those who have not 
recovered from adverse events due to agents administered more than 4 weeks 
earlier.  
 
3.2.2.  Patients may not be receiving any other investigational agents.  
 
3.2.3.  Patients with brain metastases should be excluded from this clinical trial except as 
noted above under section 3.1.3.  
 
3.2.4.  Patients with known hypersensitivity to Chinese hamster ovary cell products  or 
other recombinant human antibodies, and patients with a history of allergic  
reactions attributed to compounds of similar chemical or b iologic composition  to 
other agents used in the study.  
 
3.2.5.  Serious or non -healing wound, ulcer, or bone fracture.  
 
3.2.6.  History of abdominal fistula, gastrointestinal perforation, or intra -abdominal  
abscess within 28 days of treatment.  
 
3.2.7.  Patients with the following  invasive procedures:  
• major surgical procedure, open biopsy or significant traumatic injury  within 28 
days   prior to Day 1 therapy.  
• anticipation of need for major surgical procedures during the course of  the study.  
• minor surgical procedures, fine ne edle aspirations or core biopsies within 7 days  
prior to Day 1 of therapy. Central venous catheter placements are permitted to be 
completed 7 or more days prior to Day 1 of therapy.  However, peripherally 
inserted central catheter  (PICC  or PIC line ) may be placed at any time prior to or 
during therapy.  
 
3.2.8.  Patients with clinically significant cardiovascular or cerebrovascular disease:  
• history of cerebrovascular accident or transient ischemic attack within past 6  
months  
• uncontrolled hypertension, defined as blood pressure >150/100 mm  Hg or systolic 
BP >180 mm Hg if diastolic blood pressure <90 mm  Hg, on at least 2 repeated 
determinations on separate days within past  3 months . 
• myocardial infarction, CABG or unstable angina within the past 6  Months . 
• New Yor k Heart Association grade III or greater congestive heart  failure  
(Appendix E) , serious cardiac arrhythmia requiring medication, unstable  angina 
pectoris within past 6 months . 
• clinically significant peripheral vascular disease within past 6 months . 
  PhII-107, NCI# 8628  
  8.21.17 v 26 • Pul monary embolism, DVT, or other thromboembolic event within  past 6 months.  
 
3.2.9.  History of tumor -related or other serious hemorrhage, bleeding diathesis, or 
underlying coagulopathy.  
 
3.2.10.  PT INR >1.5 unless the patient is on full -dose warfarin.  
 
3.2.11.  Uncontrolled intercu rrent illness including, but not limited to, ongoing or  active 
infection or psychiatric illness/social situations that would limit  compliance with 
study requirements.  
 
3.2.12.  HIV-positive patients on combination antiretroviral therapy are ineligible  because 
of th e potential for pharmacokinetic interactions with VEGF Trap.  In addition, 
these patients are at increased risk of lethal infections when treated with marrow -
suppressive therapy.   
 
3.2.13.  Patients who have other current malignancies are not eligible. Patients wit h other 
malignancies are eligible if they have been continuously disease free for > 5 years 
prior to the time of randomization. Patients with prior history at any time of any in 
situ cancer, lobular carcinoma of the breast in situ, cervical cancer in situ,  atypical 
melanocytic hyperplasia or melanoma in situ are eligible. Patients with prior history 
of basal or squamous skin cancer are eligible. Patients who have had multiple 
primary melanomas are eligible.  
 
3.2.14.  Patients must not have autoimmune disorders or co nditions of immunosuppression 
that require current ongoing treatment with systemic corticosteroids (or other 
systemic immunosuppressants), including oral steroids (i.e., prednisone, 
dexamethasone) or continuous use of topical steroid creams or ointments or  
ophthalmologic steroids  or steroid inhalers .  
 
If a patient had been taking steroids, at least 2 weeks must have passed since the 
last dose.  
 
3.3. Inclusion of Women and Minorities  
Both men and women and members of all races and ethnic groups are eligible for this 
trial.  
 
 Accrual Targets  
Ethnic Category  Sex/Gender  
Females   Males   Total  
Hispanic or Latino  6 + 5 = 11 
Not Hispanic or Latino  39 + 55 = 94 
Ethnic Category: Total of all 
subjects  45 (A1) + 60 (B1) = 105 
 (C1) 
Racial Category   
  PhII-107, NCI# 8628  
  8.21.17 v 27 American Indian o r Alaskan Native  0 + 0 = 0 
Asian  2 + 1 = 3 
Black or African American  0 +      0 = 0 
Native Hawaiian or other Pacific 
Islander  0 +      0 = 0 
White  43 + 59 = 102 
Racial Category: Total of all 
subjects  45 (A2) + 60 (B2) = 105 
 (C2) 
 
These numbers are b ased on the actual historical accrual demographics at City of Hope 
National Medical Center only for patients with melanoma, but these estimates will vary 
with the other CCCP sites (or other consortia sites) accruing from the different 
catchment areas. In a ddition, the study investigators strongly believe in improving the 
accrual rates of non -white patients and therefore would like to express their strong 
commitment to make an improvement over these historical accrual numbers at COH as 
listed in the accrual targets table.  
 
4. REGISTRATION PROCEDURES  
4.1. General Guidelines  
Eligible patients will be entered on study centrally at the California Cancer Consortium 
Data Coordinating Center (DCC) at the City of Hope.  All sites should call the DCC at 
(626) 256 -4673 extensi on 65928 to verify slot availabilities.   
 
Following registration, patients should begin protocol treatment within 1 week .  Issues 
that would cause treatment delays should be discussed with the Principal Investigator.  
If a patient does not receive protoco l therapy following registration, the patient’s 
registration on the study may be canceled.  The DCC should be notified of cancellations 
as soon as possible.  
 
Except in very unusual circumstances, each participating institution will order DCTD -
supplied agen ts directly from CTEP.  Agents may be ordered by a participating site 
only after the initial IRB approval for the site has been forwarded by the Coordinating 
Center to the CTEP PIO (PIO@ctep.nci.nih.gov) except for Group studies.  
 
4.2. Registration Process  
Once  the signed informed consent has been obtained, all pretreatment evaluations have 
been performed, and patient’s eligibility has been confirmed by the data coordinating 
center a patient will be entered on study.   
 
To register a patient, the research nurse or data manager must complete the 
eligibility/registration form and contact the Consortium office (Data Coordinating 
Center for the California Cancer Consortium) at the City of Hope (626 -256-4673, ext. 
65928), FAX a copy of the completed eligibility checkl ist, required pre -study tests 
(laboratory and pathology report), signed Informed Consent, signed Patients' Bill of 
Rights and HIPAA authorization form. (FAX Number: 626 -256-8654).  See Appendix 
  PhII-107, NCI# 8628  
  8.21.17 v 28 C (“Registration Procedures”)  
 
The research nurse or data mana ger at the participating site will then call the Data 
Coordinating Center at Tel# 626 -256-4673 extension 65928 to confirm receipt of all 
registration documents. To complete the registration process, the data coordinating 
center coordinator will:  
 
• Verify the eligibility  
• Register the patient on study  
• Assign a patient accession number  
• Fax or e -mail the patient study number and dose to the participating site  
• Call the research nurse or data manager at the participating site and verbally 
confirm registr ation.  
 
5. TREATMENT PLAN  
5.1. Overall Treatment Plan  
 
Definitions:  
 
1. A cycle of IL -2: eligible patients receive high -dose IL -2 at 600,000 IU/kg IV 
every 8 hours for up to 14 doses. This constitutes one cycle of IL -2. 
2. A cycle of Aflibercept : eligible patients recei ve aflibercept at 3 mg/kg 
(combination phase) or 4 mg/kg (maintenance phase) IV every 2 weeks. This 
constitutes one cycle of aflibercept.  
3. The combination phase  (Arm A) : during this phase, IL -2 and aflibercept will 
be given concurrently. It consists of 3 co urses of combination therapy.   
a. Each course consists of 2 cycles of IL -2 as follows: high -dose IL -2  at 
600,000 IU/kg is given IV every 8 hours for up to 14 doses (one cycle), 
followed by a rest period of  1 -2 weeks and readmission for a second high 
dose I L-2 cycle for up to 14 doses (2nd cycle).  
b. In addition, aflibercept will be given concurrently at 3 mg/kg IV every 2 
weeks, but in course 1 only aflibercept will start 2 weeks prior to IL -2. 
Therefore, course 1 will consist of 5 cycles of aflibercept, whil e courses 2 
and 3 will consist of 4 cycles of aflibercept each.  
c. Based on the occurrence of treatment -related toxicities and requirements for 
dose adjustments or delays, a patient may or may not receive the full 
planned treatment, but response assessment w ill continue to be carried out 
at the end of each course.  
4. The maintenance phase  (Arm A) : only aflibercept monotherapy will be given during this 
phase at 4 mg/kg IV every 2 weeks. Response assessment will be carried out every 12 
weeks ( 6 cycles of afliberce pt) for the  first 2 years , then every 6 months ( -/+ 2 weeks) for 
years 3 -5, then yearly ( -/+ 4 weeks) afterwards .   
 
The planned treatment for Arm A consists of 3 courses of combination aflibercept and 
high dose IL -2 (the combination phase) followed by mai ntenance aflibercept 
  PhII-107, NCI# 8628  
  8.21.17 v 29 monotherapy  (aflibercept monotherapy phase) . Arm B is high dose IL -2 alone. 
Response assessment will occur at the end of each course of  combination therapy  (arm 
A) and patients without evidence of disease progression (RECIST v.1.1) or limiting 
toxicities will be offered additional courses of treatment (or maintenance aflibercept 
therapy).  
 
Management and dose modifications associated with the above adverse events are 
outlined in Section 6.  
 
Arm A: Course 1 (consists of 10 weeks) : Afliber cept to be given at 3 mg/kg  IV on day 
1 of weeks 1, 3, 5, 7 and 9. HD IL -2 will be given at 600,000 U/kg/dose IV Q8h x 5 
days (max  14 doses) starting on day 1 of weeks 3 and 5. Response assessment will be 
done during week 10.  
 
Arm A: Courses 2 and 3 (consi st of 8 weeks each) : Patients with evidence of SD, PR 
or CR on response assessment will be offered additional courses of therapy up to a total 
of 3 courses. During courses 2 and 3, aflibercept will be given at 3 mg/kg  on day 1 of 
weeks 1, 3, 5 and 7. HD IL -2 will be given at 600,000 U/kg/dose IV Q8h x 5 days (max  
14 doses) starting on day 1 of weeks 1 and 3.  
 
Arm A: Maintenance aflibercept monotherapy : Following response assessment after 
course 3 of combination therapy  and after resolution of all toxicitie s to ≤ grade 1 
(CTCAE v.4) , aflibercept monotherapy will be initiated to be administered at 4 mg/kg  
IV on Day 1of each 14 -day cycle.  Plus or minus 2 -day time windows for each treatment 
day are permitted, as are treatment delays of up to 2 weeks in case of unresolved 
toxicity.  In this case, blood pressure monitoring should be done weekly for the first 
3 weeks of the maintenance phase to ensure tolerance of the higher aflibercept 
dose.  However, if the aflibercept dose had to be reduced during the combination phase 
due to aflibercept -related toxicities, then that reduced dose will be used for maintenance 
therapy. No need for weekly monitoring of blood pressure, if the reduced dose has 
already been demonstrated to be tolerable.   
 
 
Course 1  (Arm A)  
Course  
1 Wk 
1 Wk 
2 Wk 
3 Wk 
4 Wk 
5 Wk 
6 Wk 
7 Wk 
8 Wk 
9 Wk 
10 
Aflibercept  
3 mg/kg IV X  X  X  X  X  
HD IL -2 
600,000 
U/kg/dose IV 
Q8h x 5 days   X  X      
  PhII-107, NCI# 8628  
  8.21.17 v 30  
   
 
 
Blood samples for the purpose of measuring serum VEGF levels or other laboratory 
corollary studies will be collected at the multiple time points as noted in section 9.1.1. 
See Section 9.1.1  for handling, processing, and shipping procedures . 
 
For arm B, patie nts will receive HD IL -2 alone following the institutional standard of 
care guidelines. Patients will receive a maximum of 3 courses (6 cycles; 1 course of 
IL_2 in arm B = 2 cycles of IL -2). Response assessment will be carried out at the end 
of each course . In the absence of disease progression by RECIST v.1.1, patients will 
be offered additional courses of therapy for a maximum of 3 courses (6 cycles).  
 
5.2. Aflibercept Administration   
Treatment will be administered on an outpatient basis. Reported adverse even ts and 
potential risks are described in Section 7. Appropriate dose modifications for 
aflibercept  are described in Section 6. 
 
• Patients will receive a dose of aflibercept  administered IV on Day 1 of each 14 -
day cycle. Plus or minus 2 -day time windows for e ach treatment day are 
permitted, as are treatment delays of up to 2 weeks in case of unresolved 
toxicity. Aflibercept  will be administered as an IV infusion over at least 1 hour (max  14 doses)  
Response 
Assessment           X 
Course 2  (Arm A)  Course 3  (Arm A)  
Courses 2 -3 Wk 
1 Wk 
2 Wk 
3 Wk 
4 Wk 
5 Wk 
6 Wk 
7 Wk 
8 Wk 
1 Wk 
2 Wk 
3 Wk 
4 Wk 
5 Wk 
6 Wk 
7 Wk 
8 
Aflibercept  
3 mg/kg IV  
X  X  X   
X   
X   
X   
X   
X  
HD IL -2 
600,000 
U/kg/dose 
IV Q8h x 5 
days (max  
14 doses)   
 
X   
X   
   
   
 
X   
 
X   
    
Response 
Assessment          
X   
   
   
   
X 
  PhII-107, NCI# 8628  
  8.21.17 v 31 into a  peripheral vein or a central venous catheter via a system that is compa tible 
with aflibercept . 
• The dosing solutions will be prepared by diluting aflibercept  concentrate (25 
mg/mL) with the appropriate volume of 0.9% NaCl or 5% dextrose to a final 
concentration between 0.6 mg/mL and 8 mg/mL.  This will be administered 
intraveno usly over at least 1 hour into a peripheral vein or central venous 
catheter using an infusion pump. CADD Legacy pump will be used for the 
infusion.  See Section 8.1.1 on other suitable delivery devices that are allowed.  
• Doses may be modified for toxicity a s described in Section 6. New cycles of  
therapy may not begin until any aflibercept  -related adverse events have 
adequately resolved. The Principal Investigator should be contacted for any 
treatment delay of >2 weeks duration.  
 
Special Cautions/Safety Issu es 
 
• Infusion and hypersensitivity reactions (e.g., rash, urticaria, fever, rigors,  
hypertension, wheezing, or hypoxia) may occur during or shortly after IV  
administration of protein therapeutics. The most appropriate premedication  
regimen for use with aflibercept  has not been determined, and patients  should 
not be given prophylactic premedication for acute infusion reactions  without 
prior discussion with the NCI Senior Investigator.  
 
If infusion hypersensitivity reactions occur in a given patient, then  institutional 
treatment guidelines for similar therapeutic agents should be  followed. 
Subsequent doses of aflibercept  should not be given without prior  consultation 
with the NCI Senior Investigator to discuss appropriate  premedication, and 
should be accompanie d by an increased level of vigilance  in observation and 
monitoring, administration of premedications, etc. However, dose reductions 
will not be made for acute infusion reactions.  
 
If a patient experiences a hypersensitivity or infusion reaction to 
afliberc ept, serum should be obtained to evaluate for a nti-aflibercept 
antibody formation at the time of the reaction. Please see section 9.2 for 
serum sample collection, preparation and shipping.   
 
• Since aflibercept  is a protein, it is possible that patients migh t experience 
allergic or immunologic reactions to aflibercept  administration. If a 
potentially immune -mediated event occurs during infusion of study drug, the 
ongoing infusion will be stopped immediately. Following any potentially 
immunologic toxicity, dos ing may not be resumed until the event has been 
reviewed by the investigator and the NCI Senior Investigator, and a plan of 
management has been formulated.  
 
• Hypertension is a known and potentially serious adverse event associated  with 
aflibercept  treatment . Patients should have their blood pressure  monitored 
weekly during the first cycle of therapy and prior to each infusion  of aflibercept . 
  PhII-107, NCI# 8628  
  8.21.17 v 32 Aflibercept  treatment modifications due to hypertension  should follow the 
instructions in Section  6.1. 
 
• Given the pote ntial for hemorrhage or wound healing complications with 
aflibercept , the agent should not be administered ≤ 48 hours following minor 
surgical procedures (e.g., fine needle biopsy/aspiration, placement of a central 
venous access device, or removal/biopsy o f a skin lesion), or until evidence of 
wound healing (e.g., scab formation) is observed, whichever is longer.  
 
• Given the potential for osteonecrosis of the jaw with aflibercept  in patients  who 
have had previous radiation to the head and neck, special atten tion should be 
given to any complaints of jaw pain, oral pain or sore mouth.  
 
 
• Any patient with an anti - aflibercept  (VEGF Trap) antibody level above the 
limit of quantitation who develops a grade ≥2 systemic immunologic adverse 
effect considered at least possibly related to study drug, will be permanently 
discontinued from study drug administration.  
 
• Any patient with an anti - aflibercept  (VEGF Trap) antibody level above the 
limit of quantitation who develops one of the following will be permanently 
discontinued from study treatment:  
− 24-hour urine protein total >3.5 grams, or  
− confirmed doubling of the baseline serum  creatinine to a level >1.5 x ULN 
while in a well -hydrated state, or  
− confirmed doubling of the baseline BUN to a level >1.5 x ULN while in a 
well-hydrated state  
 
5.3. Aldesleukin (Interleukin -2) Administration  
Aldesleukin (Interleukin -2, IL-2) will be adminis tered on an inpatient  basis.  Reported 
adverse events and potential risks for aldesleukin are described in Section  7.   
 
• Patients will receive a total of 6 cycles (1 cycle = 5 days) of IL -2 as described 
in section 5.1. A cycle of IL -2 may be delayed for up  to 2 weeks in case of 
unresolved toxicity.  
 
• Aldesleukin will be administered at 600,000 IU/kg IV bolus q 8 h ours during 
days 1 -5 of each cycle (maximum 14 doses per 5 day cycle).  
 
• For arm A (combination arm), d ose 1 of aldesleukin  on day 1 of each cycle  of 
IL-2 will be administered after aflibercept given on that day . 
 
• For arm A (combination arm) a n echocardiogram will be performed at baseline 
and following each course of therapy (week 10 of course 1 and week 8 of 
courses 2 and 3). Evidence of cardiac dys function compared to baseline 
  PhII-107, NCI# 8628  
  8.21.17 v 33 (decrease in ejection fraction by 25% or more) will lead to treatment 
discontinuation.  For arm B, there is no requirement to repeat the 
echocardiogram following each course of IL -2 therapy unless it is clinically 
indicated.  
 
NOTE:  Ejection fraction (EF) from baseline echocardiogram done on arm 
A must be within the institutional limits of normal as determined by the 
reading cardiologist. For patients who are required to have a baseline 
cardiac stress test , if the baseline cardi ac stress test incorporates an 
echocardiogram, then this will not need to be done again at baseline. For 
subsequent echocardiograms, evidence of cardiac dysfunction compared to 
baseline (decrease in ejection fraction by 25% or more) will lead to 
treatment discontinuation.  
 
• As all institutions participating in this protocol have established and 
experienced high dose interleukin -2 programs, t he administration of 
aldesleukin (at the protocol’ s specified dose and frequency)  and the dose 
delay/discontinuation cr iteria during a cycle of IL -2 will follow the institutional 
standard of care guidelines. A useful guide is provided by  Schwartzentruber 
DJ.  J Immunother . 2001 Jul -Aug;24(4):287 -93[21]. 
 
• For patients receiving high dose IL-2 on Arm A  or B and who t ake anti -
hypertensive medications , it is recommended that the bl ood pressure 
medications be managed as follows  (individual variations are acceptable at 
the discretion of the treating physician when it is felt in the best interest of 
the patient ): 
o On the da y of admission, the morning blood pressure medications 
should be taken, if the first dose of IL -2 is expected to be given that 
evening and not during the day. Otherwise,  if the first dose of IL -2 is 
expected to be given  during the day, then the morning blood pressure 
medications should be held. The goal is two -fold:  
▪ Avoid uncontrolled hypertension in patients holding the AM 
antihypertensive medications, if the dose will be delayed till the 
evening .  
▪ Avoid exce ssive hypotension during IL -2 if the AM dose was  
given and the first dose of IL -2 was given during the day.  
o If the first dose of IL -2 is anticipated to be given in the evening of the 
day of admission, then the blood pressure medications should be held 
for that evening and throughout IL -2 treatment unles s otherwise 
specified by the treating physician .  
o Upon completion of IL -2 therapy, the blood pressure medications 
should restarted as soon as the IL -2 induced hypotension (low blood 
pressure) has resolved. Most importantly, the blood pressure 
medications s hould be restarted before the patient is discharged home , 
unless the patient was found to be hypotensive and the treating physician 
decides to closely monitor the blood pressure before initiating the 
  PhII-107, NCI# 8628  
  8.21.17 v 34 antihypertensive medications .  
 
5.4. General  Concomitant Medi cation and  Supportive Care Guidelines  
Because there is a potential for interaction of aflibercpt  with other concomitantly  
administered drugs, the case report form must capture the concurrent use of all other  
drugs, over -the-counter medications, or alternat ive therapies. All patient treatments  30 
days prior to registration onto the study, at any time during the study, and up to 60  
days after the end of the study will be considered as concomitant treatments. Any  
treatment administered following the withdrawal  from the study that is used to treat  
new or unresolved events related to the study treatment, is also considered as  
concomitant treatment. The type, dose, and route of administration for all  concomitant 
treatments must be documented in the case report for m (CRF).  
 
Concomitant medications should be kept to a minimum during the study. However, if  
these are considered necessary for the patient’ s welfare and are unlikely to interfere  
with the investigational products, they may be  given at the discretion of the  
investigator and recorded in the CRF.  
 
The following concomitant treatments are permitted during this study:  
 
• all supportive measures (including hyperalimentation and blood transfusions) 
consistent with optimal patient care.  
 
• medications for chronic pain management, including narcotic analgesics, are 
permitted as clinically indicated.  
 
• therapeutic use of hematopoietic growth factors is permitted at the 
investigator’s discretion and should follow American Society of Clinical 
Oncology guidelines for their us e. 
 
5.5. Duration of Therapy  
In the absence of treatment delays due to adverse events, treatment may continue for    
per study protocol until one of the following criteria applies:  
 
 Disease progression,  
 
 Intercurrent illness that prevents further administration  of treatment,  
 
 Unacceptable adverse events(s),  
 
 Patient decides to withdraw from the study, or  
 
 General or specific changes in the patient's condition render the patient 
unacceptable for further treatment in t he judgment of the investigator,  
 
  PhII-107, NCI# 8628  
  8.21.17 v 35  Arterial thr omboembolic events including cerebrovascular accidents, 
myocardial infarctions, transient ischemic attacks, new onset or worsening 
of pre -exiting angina , 
 
 Evidence of cardiac dysfunction (decrease in ejection fraction by 25% or 
more) compared to baseline  noted on study echocardiogram testing,  
  
5.6. Duration of Follow Up  
Patients will be followed for 5 years  after removal from study or until death, whichever 
occurs first.  Patients removed from study for unacceptable adverse events will be 
followed until resolut ion or stabilization of the adverse event.  The frequency and the  
type of evaluations during this follow up period will follow institutional standard of 
care practices . For patients who wish not to follow with a study investigator, they can 
be followed by their treating physician of choice and also following local standard of 
care practices . Data on disease progression and survival will be collected on all patients  
every 3 -4 months.  
 
6. DOSING DELAYS/DOSE MODIFICATIONS  (Aflibercept)  
NOTE:  As all institutions participating in this protocol have established and 
experienced high dose interleukin -2 programs, the administration of aldesleukin (at the 
protocol’s specified dose and frequency) and the dose delay/discontinuation criteria during 
a cycle of IL -2 will fol low the institutional standard of care guidelines. A useful guide is 
provided by Schwartzentruber DJ.  J Immunother . 2001 Jul -Aug;24(4):287 -93[21]. 
 
Aflibercept doses will be modified as shown below. Doses reduced for drug -related toxicity  
should ge nerally not be re -escalated, even if the reduced dose produces minimal or no 
toxicity.  
 
Dose Levels for Dose Reduction  
 
 
 
The lowest dose level will be utilized for patients  requiring multiple simultaneous dose  
adjustments. No more than 2 aflibercept dose reductions per patient are permitted.  
Patients  requiring more than 2 aflibercept dose reductions will have aflibercept 
permanently discontinued . Unless  otherwise indicated, all grades of  toxicity refer to NCI 
CTCAE v.4 .0 grades.   
 Dose Level  Aflibercept  
0 4 mg/kg  3 mg/kg  
-1 3 mg/kg  2 mg/kg  
-2 2 mg/kg  1 mg/kg  
  PhII-107, NCI# 8628  
  8.21.17 v 36 • Frequent blood pressure monitoring is important in patients receiving aflibercept .  
Patients should seek immediate  medical advice if their blood pressure (BP) 
exceeds 180 mmHg  (systolic) or 105 mmHg  (diastolic) at any time and should also 
be encouraged to  contact their physician if they are concerned about any symptoms 
that may be associated with high blood pressure ( e.g., headache).  
 
• Renal function (creatinine and urinary protein) should be frequent ly monitored as  
suggested by the pathologic changes noted in animal studies and evidence from  
studies of other antiangiogenic agents. Specific guidelines for management of 
proteinuria are presented in Section 6.2. 
 
In the absence of disease progression or limiting toxicities, patients may continue IL -
2 therapy per study protocol even if aflibercept was permanently discontinued.  
 
6.1. Management of Hypertension  
Increases in blood pressure ( BP) and cases of hypertension have been associated with 
many drugs acting  on the VEGF pathway. The proposed mechanism for this increase 
is through inhibition  of VEGF -induced peripheral vasodilation. Hypertension 
following aflibercept treatment has been seen in animal studies as well as clinical trials.   
 
Notes : 
 
• While patients are receiving treatment with aflibercept , the early initiation 
of antihypertensive treatment for grade 1 or 2 hypertension to minimize 
more severe  or persistent hypertension is not considered a grade 3 adverse 
event.  
 
• Decisions to hold or decrease the afli bercept dose during treatment must be  
based on BP readings taken in the clinic by a medical professional.  
 
• In case of new -onset or worsening (grade ≥ 2) hypertension, see chart on page 
24. Other preferred treatment options include calcium -channel blockers or 
alpha -1 blockers. Angiotensin converting enzyme inhibitors or angiotensin II 
antagonists  may also be appropriate in the absence of significant renal 
dysfunction or suspicion of renovascular disease. Beta blockers and diuretics 
should be used  with cautio n due to their relatively slow onset of action. 
Ultimately,  antihypertensive treatment must be individualized based on the 
presence of  comorbidity such as diabetes, cardiovascular, or renal disease, 
additionally taking  into account the safety and efficacy of any prior 
antihypertensive therapy  received. In addition, oral and/or intravenous sodium 
intake should be carefully  monitored in these patients. Blood pressure and 
electrolyte monitoring should be  performed at least once or twice weekly until 
stable blo od pressure control is  achieved. Early consultation with a cardiologist 
is strongly encouraged in case of  uncontrolled hypertension.  
 
  PhII-107, NCI# 8628  
  8.21.17 v 37 • The following table is a recommendation:  
 
 
Hypertension Monitoring and Management  
Grade  
(CTCAEv4.0)  Antihypertensive  
Ther apy Blood Pressure Monitoring  Aflibercept Dose  
Modification  
Grade 1  • None  (Consider initiating 
therapy of choice per MD &/ OR 
Increase doses of existing  
medications)  
• Baseline  • Standard monitoring per 
study protocol  
• In addition, s tart daily BP 
monitoring at home and 
plan to start treatment for 
grade 2 HTN    No Change  
Grade 2 - Mild  • Initiate therapy of choice per MD 
&/OR 
• Increase doses of existing  
medications until BP controlled or 
at maximum dose  • Increased frequency of 
monitoring until stabilized  No Change  
Persistent Moderate  
Hypertension  
 
(Definition: Patients 
who initiate 
antihypertensive 
therapy or have 
additional 
medications  added to 
existing therapy but 
their BP is not 
controlled to grade 1 
or less)  • Initiate therapy of choice per MD 
&/OR 
• Increase doses  or number of 
medications until BP controlled or 
at maximum dose  • Increased frequency of 
monitoring until stabilized 
e.g. every 48 hours  
• Supervised by healthcare 
professional  If partial or no 
control and BP  
still in a moderate 
range for  
24-48 hours, hold 
aflibercept and add 
additional drugs , 
increasing to a  
maximum dose until  
hypertension 
controlled;  
 
Monitor for 
hypotension;  
 
Decrease 
aflibercept by 1 
dose level  
Grade 3 - Severe  • Start immediate therapy with 2 
drug combination including at 
least a DHP - CCB  
• Escalate doses to achieve optimal 
control of BP, up to the maximum 
dose 
• If partial or no BP control, add 
additional drugs up to 4; increase 
to optimal or maximum doses of 
all drugs  • Increased frequency of 
monitoring until stabilized 
e.g. every 48 hours  
• Supe rvised by healthcare 
professional  Hold aflibercept ; If 
control of BP in the 
Mild range, restart 
VEGF TRAP at the  
next lower dose 
level  
 
If partial or no 
control,  
discontinue 
therapy per 
investigator  
 
Stop aflibercept  if 
hypertension is 
symptomatic,  
hospita lize patient 
  PhII-107, NCI# 8628  
  8.21.17 v 38 for 
management of BP  
Grade 4  
Hypertensive Crisis  • Optimal management with 
intensive support IV in ICU  • Hospitalize patient for 
management  Off protocol 
therapy;  
 
Discontinue 
aflibercept;  
 
Monitor closely for  
hypotension  
• Abbreviations: dihydropy ridine calcium -channel blockers (DHP -CCB), selective beta blockers (BB), 
Angiotensin Converting Enzyme Inhibitors (ACEI), Angiotensin II Receptor Blockers (ARB)  
• If patients require a delay of > 2 weeks for management of hypertension, discontinue aflibercep t therapy  
• If patients require > 2 dose reductions, discontinue aflibercept therapy  
• Patients may have up to 2 drugs for management of hypertension prior to any dose reduction in aflibercept  
• 24-48 hour should elapse between modifications of antihypertensive therapy  
• Hypertension should be graded using the NCI CTCAEv4.0  
 
6.2. Proteinuria  
A 24 -hour urine collection for quantitative protein determination must be obtained for 
a urine protein:creatinine ratio (UPCR) >1. Instructions for dose modifications due to  
protei nuria are summarized below.  
 
Proteinuria  Action to be Taken  
Grade ≤ 2  No modification.  
Grade 3 (4+ or >3.5 grams/24 hours)  • Delay dosing until recovery to urinary protein <2 grams/24 hours.  
• Reduce subsequent doses of aflibercept by 1 dose level if proteinuria 
does not recover to <2 grams/24 hours within 2 weeks.  
• Discontinue patients from aflibercept treatment who experience 
recurrent Grade 3 toxicity after 2 dose reductions.  
Grade 4  Consult a nephrologist and discontinue patient from aflibercept  treatment.  
 
6.3. Other Adverse Events  
• No dose modifications should be perf ormed for adverse events (such as alopecia) 
that do not directly affect the patient’s physical health.   
 
• Dose -reduce aflibercept for grade 3 or 4 aflibercept -related adverse events aside 
from hypertension and proteinuria even if therapy is not delayed.  Exception:  
Patients with grade 3 or 4 electrolyte or other laboratory abnormalities that could 
be corrected within 48 hours to grade 2 or less could be retreated with the same 
dose of aflibercept. Re-treatment with aflibercept could be done as soon as these 
abnormalities have been corrected to grade 2 or less.    
 
• Any other drug -related adverse event considered serious or which causes a >2 -week 
  PhII-107, NCI# 8628  
  8.21.17 v 39 study treatment delay will result in the reduction of subsequent doses by one dose 
level.  If patient cannot restart  therapy after 2 weeks  delay, contact the Principal 
Investigator for discussion of removing patient from study.  
 
• Other aflibercept dose reductions not described above may be performed at the 
discretion of the investigator after discussion with the NCI Seni or Investigator, 
provided that criteria for patient withdrawal from study tre atment (described in 
Section 5.5 ) have not been met.  
 
7. ADVERSE EVENTS:  LIST AND REPORTING REQUIREMENTS  
Adverse event (AE) monitoring and reporting is a routine part of every clin ical trial.  The 
following list of AEs (Section 7.1) and the characteristics of an observed AE (Section 7.2) 
will determine whether the event requires expedited (via CTEP -AERS ) reporting in 
addition  to routine reporting.  
 
7.1. Comprehensive Adverse Events and P otential Risks List s (CAEPRs)  
 
7.1.1.  CAEPR for Aflibercept (VEGF -Trap, NSC 724770)  
 
   
The Comprehensive Adverse Event and Potential Risks list (CAEPR) provides a 
single list of reported and/or potential adverse events (AE) associated with an 
agent using a unifo rm presentation of events by body system. In addition to the 
comprehensive list, a subset, the Specific Protocol Exceptions to Expedited 
Reporting (SPEER), appears in a separate column and is identified with bold and 
italicized text. This subset of AEs (SP EER) is a list of events that are protocol 
specific exceptions to expedited reporting to NCI via CTEP -AERS  (except as 
noted below).  Refer to the 'CTEP, NCI Guidelines: Adverse Event Reporting 
Requirements'  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/adverse_even
ts.htm  for further clarification. Frequency is provided based on 811 patients. 
Below is the CAEPR for aflibercept (VEGF -Trap) . 
 
NOTE : Report AEs on the SPEER ONLY IF  they exceed the grade noted 
in parentheses next to the AE in the SPEER.  If this CAEPR is part of a 
combination protocol using multiple investigational agents and has an AE 
listed on different SPEERs, use the lower of the grades to determine if 
expedited reporting is required.  
 
Version 2.6, November 24, 20151 
  PhII-107, NCI# 8628  
  8.21.17 v 40  
 Adverse Events with Possible  
 Relationship to Ziv -aflibercept (VEGF -Trap, AVE 0005)  
 (CTCAE 4.0 Term)  
[n= 811]    
 Specific Protocol Exceptions 
to Expe dited Reporting 
(SPEER)  
Likely (>20%)  Less Likely (<=20%)  Rare but Serious (<3%)    
BLOOD AND LYMPHATIC SYSTEM DISORDERS    
Anemia     Anemia (Gr 2)  
  Febrile neutropenia    
  Hemolytic uremic 
syndrome    
  Thrombotic 
thrombocytopenic 
purpura    
CARDIAC DISORDERS    
  Chest pain - cardiac    
  Myocardial infarction    
  Restrictive 
cardiomyopathy    
  Cardiac disorders - 
Other (intracardiac 
thrombus)    
GASTROINTESTINAL DISORDERS    
Abdominal pain     Abdominal pain (Gr 2)  
 Anal mucositis     
 Constipatio n   Constipation (Gr 2)  
 Diarrhea    Diarrhea (Gr 2)  
  Gastrointestinal fistula2   
  Gastrointestinal 
perforation3   
 Mucositis oral     
Nausea     Nausea (Gr 2)  
 Vomitin g   Vomiting (Gr 2)  
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS    
 Edema limbs    Edema limbs (Gr 2)  
Fatigue     Fatigue (Gr 3)  
 Fever    Fever (Gr 2)  
 Pain    
IMMUNE SYSTEM DISORDERS    
 Allergic reaction      
INFECTIONS AND INFESTATIONS    
 Infection4    
INJURY, POISONING AND PROCEDURAL COMPLICATIONS    
  PhII-107, NCI# 8628  
  8.21.17 v 41  
 Adverse Events with Possible  
 Relationship to Ziv -aflibercept (VEGF -Trap, AVE 0005)  
 (CTCAE 4.0 Term)  
[n= 811]    
 Specific Protocol Exceptions 
to Expe dited Reporting 
(SPEER)  
Likely (>20%)  Less Likely (<=20%)  Rare but Serious (<3%)    
 Wound complication     
 Wound dehiscence     
INVESTIGATIONS    
 Alanine aminotransferase 
increased     
 Alkaline phosphatase 
increased     
 Aspartate 
aminotransferase 
incre ased    
Lymphocyte count 
decreased     Lymphocyte count decreased 
(Gr 4)  
 Neutrophil count 
decreased    Neutrophil count decreased 
(Gr 4)  
 Platelet count decreased    Platelet count decreased (Gr 4)  
 Weight loss     
 White blood cell 
decreased    White blo od cell decreased (Gr 
2) 
METABOLISM AND NUTRITION DISORDERS    
Anorexia     Anorexia (Gr 2)  
 Dehydration     
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS    
 Arthralgia    Arthralgia (Gr 2)  
 Back pain     
 Myalgia    Myalgia (Gr 2)  
NERVOUS SYSTEM DISOR DERS    
 Dizziness     
Headache     Headache (Gr 3)  
  Ischemia 
cerebrovascular   Ischemia cerebrovascular (Gr 
2) 
  Reversible posterior 
leukoencephalopathy 
syndrome    
  Transient ischemic 
attack    
RENAL AND URINARY DISORDERS    
  Acute kidney injury    
  PhII-107, NCI# 8628  
  8.21.17 v 42  
 Adverse Events with Possible  
 Relationship to Ziv -aflibercept (VEGF -Trap, AVE 0005)  
 (CTCAE 4.0 Term)  
[n= 811]    
 Specific Protocol Exceptions 
to Expe dited Reporting 
(SPEER)  
Likely (>20%)  Less Likely (<=20%)  Rare but Serious (<3%)    
 Proteinuria    Proteinuria (Gr 3)  
  Renal disorders - Other 
(nephrotic syndrome)    
REPRODUCTIVE SYSTEM AND BREAST DISORDERS    
 Genitourinary system 
fistula5    
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS    
 Cough    Cough  (Gr 2)  
 Dyspnea    Dyspnea (Gr 3)  
 Pharyngolaryngeal pain     
Voice alteration     Voice alteration (Gr 2)  
 Respiratory, thoracic, and 
mediastinal disorders - 
Other (rhinorrhea)     
SKIN AND SUBCUTANEOUS TISSUE DISORDERS    
 Alopecia     
 Palmar -plantar 
erythrodysesthesia 
syndrome     
 Rash maculo -papular     
 Skin hyperpigmentation     
VASCULAR DISORDERS    
Hypertension     Hypertension (Gr 3)  
 Thromboembolic event    Thromboembolic event (Gr 3)  
 Vascular disorders - 
Other (hemorrhage)6   Vascular disorders - Other 
(hemorrhage)6 (Gr 2)  
 
1This table wil l be updated as the toxicity profile of the agent is revised. Updates will be 
distributed to all Principal Investigators at the time of revision. The current version can be 
obtained by contacting PIO@CTEP.NCI.NIH.G OV. Your name, the name of the investigator, 
the protocol and the agent should be included in the e -mail.  
2Gastrointestinal fistulas may include: Anal fistula, Colonic fistula, Duodenal fistula, Esophageal 
fistula, Gastric fistula, Gastrointestinal fistul a, Rectal fistula, and other sites under the 
GASTROINTESTINAL DISORDERS SOC.  
 
3Gastrointestinal perforation imay include: Colonic perforation, Duodenal perforation, 
  PhII-107, NCI# 8628  
  8.21.17 v 43 Esophageal perforation, Gastric perforation, Ileal perforation, Jejunal perforation, Rectal  
perforation, and Small intestinal perforation under the GASTROINTESTINAL DISORDERS 
SOC.  
 
4Infection may include any of the 75 infection sites under the INFECTIONS AND 
INFESTATIONS SOC.  
 
5Genitourinary fistulas may include: female genital tract fistula, ut erine fistula, and vaginal 
fistula.  
 
6The majority of hemorrhage events were mild.  Major events, defined as symptomatic bleeding 
in a critical area or organ (e.g., eye, GI hemorrhage, GU hemorrhage, respiratory hemorrhage), 
and nervous system [including f atal intracranial hemorrhage and cerebrovascular accident] have 
been reported.  
 
Adverse events reported on Ziv-aflibercept (VEGF -Trap, AVE 0005) trials but for which 
there is insufficient evidence to suggest that there was a reasonable possibility that  Ziv-
aflibercept (VEGF -Trap, AVE 0005) caused the event.  
 
BLOOD AND LYMPHATIC SYSTEM DISORDERS  - Blood and lymphatic system 
disorders - Other (hemoglobin increased); Hemolysis  
CARDIAC DISORDERS  - Acute coronary syndrome; Cardiac disorders - Other (left 
ventri cular diastolic dysfunction); Heart failure; Left ventricular systolic dysfunction; 
Pericarditis; Supraventricular tachycardia  
EAR AND LABYRINTH DI SORDERS  - Tinnitus; Vertigo  
ENDOCRINE DISORDERS  - Hyperthyroidism; Hypothyroidism  
EYE DISORDERS  - Blurred vis ion; Extraocular muscle paresis; Eye disorders - Other 
(blindness transient); Eye disorders - Other (diplopia); Vitreous hemorrhage  
GASTROINTESTINAL DIS ORDERS  - Abdominal distension; Colitis; Dental caries; Dry 
mouth; Dyspepsia; Dysphagia; Esophageal pain;  Flatulence; Gastritis; Gastrointestinal disorders 
- Other (early satiety); Gastrointestinal disorders - Other (enteric fistula); Gastrointestinal 
disorders - Other (eructation); Gastrointestinal disorders - Other (gastrointestinal necrosis); 
Gastrointesti nal disorders - Other (hiatal hernia);Gastrointestinal disorders - Other (intestinal 
ischemia); Gastrointestinal disorders - Other (pneumatosis intestinalis); Gastrointestinal 
disorders - Other (peritonitis); Gingival pain; Hemorrhoids; Ileus; Oral pain; R ectal mucositis; 
Rectal ulcer; Small intestinal mucositis; Small intestinal obstruction  
GENERAL DISORDERS AN D ADMINISTRATION SIT E CONDITIONS  - Edema face; 
Edema trunk; Facial pain; Infusion related reaction; Injection site reaction; Non -cardiac chest 
pain 
HEPATOBILIARY DISORD ERS  - Cholecystitis  
INJURY, POISONING AN D PROCEDURAL COMPLIC ATIONS  - Biliary anastomotic 
leak; Gastric anastomotic leak; Vascular access complication  
INVESTIGATIONS  - Activated partial thromboplastin time prolonged; Blood bilirubin 
increased; Creatinine increased; Ejection fraction decreased; GGT increased; Investigations - 
Other (elevated LDH)  
METABOLISM AND NUTRI TION DISORDERS  - Hypercalcemia; Hyperglycemia; 
  PhII-107, NCI# 8628  
  8.21.17 v 44 Hyperkalemia; Hypoalbuminemia; Hypocalcemia; Hypoglycemia; Hypokalemia; 
Hypoma gnesemia; Hyponatremia; Hypophosphatemia  
MUSCULOSKELETAL AND CONNECTIVE TISSUE DI SORDERS  - Arthritis; Avascular 
necrosis; Chest wall pain; Generalized muscle weakness; Head soft tissue necrosis; Joint range 
of motion decreased; Muscle weakness upper limb; Musculoskeletal and connective tissue 
disorder - Other (muscle spasms); Musculoskeletal and connective tissue disorder - Other 
(musculoskeletal stiffness); Musculoskeletal and connective tissue disorder - Other (rotator cuff 
tear); Myositis; Neck pain; Ost eonecrosis of jaw; Pain in extremity; Pelvic soft tissue necrosis  
NEOPLASMS BENIGN, MA LIGNANT AND UNSPECIF IED (INCL CYSTS AND 
POLYPS)  - Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other (tumor 
hemorrhage)  
NERVOUS SYSTEM DISOR DERS  - Amnesia; Ataxia; Cognitive disturbance; Dysgeusia; 
Encephalopathy; Extrapyramidal disorder; Leukoencephalopathy; Memory impairment; 
Paresthesia; Peripheral sensory neuropathy; Seizure; Syncope; Vagus nerve disorder  
PSYCHIATRIC DISORDER S - Anxiety; Confus ion; Depression; Insomnia; Psychiatric 
disorders - Other (mental status change); Psychosis  
REPRODUCTIVE SYSTEM AND BREAST DISORDERS  - Irregular menstruation  
RESPIRATORY, THORACI C AND MEDIASTINAL DI SORDERS  - Hypoxia; Laryngeal 
mucositis; Nasal congestion; P haryngeal mucositis; Pleural effusion; Pneumonitis; 
Pneumothorax; Pulmonary fibrosis; Respiratory, thoracic and mediastinal disorders - Other 
(nasal dryness); Respiratory, thoracic and mediastinal disorders - Other (tracheal fistula); 
Respiratory, thoracic  and mediastinal disorders - Other (septal perforation); Tracheal mucositis  
SKIN AND SUBCUTANEOU S TISSUE DISORDERS  - Dry skin; Hyperhidrosis; Nail loss; 
Rash acneiform; Skin and subcutaneous tissue disorders - Other (hyperemia); Skin ulceration  
VASCULAR DI SORDERS  - Hematoma; Hypotension; Peripheral ischemia; Phlebitis  
 
 
Note : Ziv -aflibercept (VEGF -Trap, AVE 0005) in combination with other agents could cause an 
exacerbation of any adverse event currently known to be caused by the other agent, or the 
combinat ion may result in events never previously associated with either agent.  
 
 
7.1.2.  CAEPR for Interleukin -2 (NSC 373364)  
 
The Comprehensive Adverse Event and Potential Risks list (CAEPR) provides a 
single list of reported and/or potential adverse events (AE) associa ted with an agent 
using a uniform presentation of events by body system. In addition to the 
comprehensive list, a subset, the Agent Specific Adverse Event List (ASAEL), 
appears in a separate column and is identified with bold and italicized text. This 
subset of AEs (ASAEL) contains events that are considered 'expected' for expedited 
reporting purposes only. Refer to the 'CTEP, NCI Guidelines: Adverse Event 
Reporting Requirements'  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/adverse_even
ts.htm  for further clarification. The CAEPR does not provide frequency data; refer 
to the Investigator's Brochure for this information. Below is the CAEPR  for 
interleukin -2. 
  PhII-107, NCI# 8628  
  8.21.17 v 45  
 
 
Version 1.1, December 14, 2009  
Adverse Events with Possible  
 Relationship to Interleukin -2  
(CTCAE 4.0 Term)    
 EXPECTED AEs FOR CTEP -
AERS  REPORTING  
 
Agent Specific Adverse Event 
List 
(ASAEL)  
 
BLOOD AND LYMPHATIC SYSTEM DISORDERS   Expected  
 Anemia   Anemia  
CARDIAC DISORDERS    
 Conduction disorder   Conduction disorder  
 Left ventricular systolic dysfunction   Left ventricular systolic 
dysfunction  
 Myocardial infarction    
 Myocarditis   Myocarditis  
 Palpitations   Palpitations  
 Sinus tachycardia   Sinus tachycardia  
 Supraventricular tachycardia   Supraventricular tachycardia  
 Ventricular arrhythmia   Ventricular arrhythmia  
EAR AND LABYRINTH DI SORDERS    
 Hearing impaired   Hearing impaired  
EYE DISORDERS    
 Blurred vision   Blurred v ision  
GASTROINTESTINAL DIS ORDERS    
 Abdominal pain    
 Diarrhea   Diarrhea  
 Dry mouth   Dry mouth  
 Gastrointestinal disorders - Other 
(Perforation, GI – Select)    
 Gastrointestinal disorders - Other (small 
bowel fistula)   Gastrointestinal disorders - Other 
(small bowel fistula)  
 Mucositis oral   Mucositis oral  
 Nausea   Nausea  
 Vomiting   Vomiting  
GENERAL DISORDERS AN D ADMINISTRATION SIT E 
CONDITIONS    
 Chills   Chills  
 Edema limbs   Edema limbs  
  PhII-107, NCI# 8628  
  8.21.17 v 46  Fatigue   Fatigue  
 Fever   Fever  
IMMUNE SYSTEM DISORD ERS   
 Allergic reaction   Allergic reaction  
 Autoimmune disorder   Autoimmune disorder  
INFECTIONS AND INFES TATIONS    
 Infections and Infestations – Other 
(Infection – Select)   Infections and Infestations – Other 
(Infection – Select)  
INVESTIGATIONS    
 Activated partial thromboplastin time 
prolonged   Activated partial thromboplastin 
time prolonged  
 Alanine aminotransferase increased   Alanine aminotransferase 
increased  
 Alkaline phosphatase increased   Alkaline phosphatase increased  
 Aspartate aminotransfer ase increased   Aspartate aminotransferase 
increased  
 Blood bilirubin increased   Blood bilirubin increased  
 Creatinine increased   Creatinine increased  
 GGT increased   GGT increased  
 INR increased   INR increased  
 Platelet count decreased   Platelet count  decreased  
 Weight gain   Weight gain  
 White blood cell decreased   White blood cell decreased  
METABOLISM AND NUTRI TION DISORDERS    
 Acidosis   Acidosis  
 Anorexia    
 Hyperuricemia   Hyperuricemia  
 Hypocalcemia   Hypocalcemia  
 Hypoglycemia   Hypoglycemia  
 Hypomagnesemia    
 Hyponatremia   Hyponatremia  
MUSCULOSKELETAL AND CONNECTIVE TISSUE 
DISORDERS    
 Arthralgia   Arthralgia  
 Myalgia   Myalgia  
 Myositis   Myositis  
NERVOUS SYSTEM DISOR DERS    
 Depressed level of consciousness   Depressed level of conscious ness 
 Dizziness    
 Headache   Headache  
 Memory impairment   Memory impairment  
 Nervous system disorders - Other (sleep  Nervous system disorders - Other 
  PhII-107, NCI# 8628  
  8.21.17 v 47 disturbances)  (sleep disturbances)  
 Peripheral sensory neuropathy   Peripheral sensory neuropathy  
 Seizure   Seizure  
PSYCHIATRIC DISORDER S   
 Anxiety    
 Confusion   Confusion  
 Personality change   Personality change  
 Psychosis   Psychosis  
RENAL AND URINARY DI SORDERS    
 Acute kidney injury   Acute kidney injury  
RESPIRATORY, THORACI C AND MEDIASTINAL 
DISORDERS    
 Adult respiratory distress syndrome   Adult respiratory distress 
syndrome  
 Allergic rhinitis   Allergic rhinitis  
 Apnea    
 Cough    
 Dyspnea   Dyspnea  
SKIN AND SUBCUTANEOU S TISSUE DISORDERS    
 Alopecia   Alopecia  
 Pruritus   Pruritus  
 Rash mac ulo-papular   Rash maculo -papular  
VASCULAR DISORDERS    
 Capillary leak syndrome   Capillary leak syndrome  
 Hypotension   Hypotension  
 Peripheral ischemia    
 Thromboembolic event    
 Vascular disorders - Other (vasodilation)    
 
1 This table will be updat ed as the toxicity profile of the agent is revised.  Updates will be 
distributed to all Principal Investigators at the time of revision.  The current version can be obtained 
by contacting PIO@CTEP.NCI.NIH.GOV .  Your name, the name of the investigator, the  protocol 
and the agent should be included in the e -mail.  
 
Also reported on interleukin -2 trials but with the relationship to interleukin -2 still 
undetermined:  
 
CARDIAC DISORDERS  - Mobitz type I; Pericardial effusion  
EYE DISORDERS  - Eye disorders - Other ( mydriasis)  
GASTROINTESTINAL DIS ORDERS  - Gastrointestinal disorders – Other (Hemorrhage, GI – 
Select); Pancreatitis  
GENERAL DISORDERS AN D ADMINISTRATION SIT E CONDITIONS  - General 
disorders and administration site conditions - Other (phospholipid syndrome); Hypothermia; 
Multi -organ failure  
  PhII-107, NCI# 8628  
  8.21.17 v 48 INFECTIONS AND INFESTATIONS – Infections and infestations – Other (Infection 
(documented clinically or microbiologically with Grade 3 or 4 neutrophils [ANC <1.0 x 10e9/L]) 
– Select)  
MUSCULOSKELETAL AND CONNECTIVE TISSUE DI SORDERS  - Soft tissue necrosis 
lower limb  
NERVOUS SYSTEM DISOR DERS  - Encephalopathy; Syncope  
PSYCHIATRIC DISORDER S - Agitation  
RENAL AND URINARY DI SORDERS  - Renal and urinary disorders - Other (acute tubular 
necrosis)  
RESPIRATORY, THORACI C AND MEDIASTINAL D ISORDERS  - Bronchopulmonary 
hemorrhage; Bronchospasm; Hypoxia; Pneumothorax; Pulmonary edema  
VASCULAR DISORDERS  – Phlebitis , splenic infarction (in a patient with a history of 
thrombocytosis treated with the combination of IL2 and aflibercept).  
 
Note : Inte rleukin -2 in combination with other agents could cause an exacerbation of any adverse 
event currently known to be caused by the other agent, or the combination may result in events 
never previously associated with either agent.  
 
 
7.1.2.1. Protocol -Specific Expedite d Adverse Event Reporting Exclusions  for 
Interleukin -2 related Adverse Events  
 
• For this protocol only , certain interleukin -2 related AEs/grades are exceptions to 
the Expedited Reporting Guidelines and do not require expedited reporting ( i.e., 
CTEP -AERS ).  The following interleukin -2 related AEs must be reported only if 
they exceed the grade listed below through the routine reporting mechanism 
(Section 7.4):  
 
 Lymphocyte count decreased (Gr 4)  
 Neutrophil count decreased (Gr 4)  
 Platelet count decreased (Gr  4) 
 White blood cell decreased (Gr 2)  
 Dyspnea (Gr 3)  
 Fatigue (Gr 3)  
 Headache (Gr 3)  
 Nausea (Gr 3)  
 Vomiting (Gr 2)  
 Diarrhea (Gr 2)  
 Anemia (Gr 2)  
 Abdominal pain (Gr 2)  
 Fever (Gr 2)  
 Edema limbs (Gr 2)  
  Anorexia (Gr 2)  
 Arthralgia (Gr 2)  
 Myalg ia (Gr 2)  
 Cough (Gr 2)  
  PhII-107, NCI# 8628  
  8.21.17 v 49  Hypophosphatemia, Gr 3  
 
7.2. Adverse Event Characteristics  
• CTCAE term (AE description) and grade:   The descriptions and grading scales 
found in the revised NCI Common Terminology Criteria for Adverse Events 
(CTCAE) version 4.0 will be utilized for AE reporting.   All appropriate treatment 
areas should have access to a copy of the CTCAE version 4.0.   A copy of the 
CTCAE version 4.0 can be downloaded from the CTEP web site 
(http://ctep.cancer.gov ). 
 
• ‘Expectedness’ : AEs can be ‘Unexpected’ or ‘Expected’ (see Section 7.1 above) 
for expedited reporting purposes only.  ‘Expected’ AEs (the ASAEL) are bold and 
italicized  in the CAEPR (Section 7.1.1).  
 
• Attribution  of the AE:  
- Definite – The AE is clearly related  to the study treatment.  
- Probable – The AE is likely related to the study treatment.  
- Possible – The AE may be related  to the study treatment.  
- Unlikely – The AE is doubtfully related to the study treatment.  
- Unrelated – The AE  is clearly NOT related  to the study treatment.  
 
7.3. Expedited Adverse Event Reporting  
 
7.3.1.  Expedited AE reporting for this study must use CTEP -AERS  (CTEP - Adverse 
Event Reporting System), accessed via the CTEP home page 
(http://ctep.cancer.gov ).  The reporting procedures to be followed are presented in 
the “CTEP, NCI Guidelines: Adverse Event Reporting Requirements” which can 
be downloaded from the CTEP home page ( http://ctep.cancer.gov ).  These 
requirements are briefly outlined in the table below (Section 7.3. 2). 
 
CTEP -AERS  is programmed for automatic electronic distribution of reports to the 
following individuals:  Study Coordinator of the Lead Organization, Prin cipal 
Investigator, and the local treating physician.  CTEP -AERS  provides a copy feature 
for other e -mail recipients.   PLEASE INCLUDE CCCP@COH.ORG  ON ALL 
CTEP -AERS  REPORTS SUBMITTED.  
 
7.3.2.  Expedited Reporting Guidelines – CTEP-AERS  Reporting Requirements for 
Adverse Events that occur within 30 Days1 of the Last Dose of the Investigational 
Agent on Phase 2 and 3 Trials  
 
Phase 2 and 3 Trials  
  
Grade 1   
Grade 2   
Grade 2   
Grade 3   
Grade 3  Grades  
4 & 52 Grades  
4 & 52 
Unexpected   
and 
Expected   
Unex -
pected   
 
Expected  Unexpected  Expected  Unex - 
pected  Expected  with  without with  without 
  PhII-107, NCI# 8628  
  8.21.17 v 50 Hospitali -
zation  Hospitali - 
zation  Hospitali - 
zation  Hospitali - 
zation  
Unrelated  
Unlikely  Not 
Required  Not 
Required  Not 
Required  10 
Calend ar 
Days  Not 
Required  10 
Calendar  
Days  Not 
Required  10 
Calendar  
Days  10 
Calendar  
Days  
Possible  
Probable  
Definite  Not 
Required  10 
Calendar  
Days  Not 
Required  10 
Calendar  
Days  10 
Calendar  
Days  10 
Calendar  
Days  Not 
Required  24-Hour;  
5 Calendar  
Days  10 
Calendar  
Days  
1 Adverse events with attribution of possible, probable, or definite that occur greater  than 30 days after the last 
dose of treatment with an agent under a CTEP IND require reporting as follows:  
CTEP -AERS  24-hour notification followed by complete re port within 5 calendar days for:  
• Grade 4 and Grade 5 unexpected events  
 CTEP -AERS  10 calendar day report:  
• Grade 3 unexpected events with hospitalization or prolongation of hospitalization  
• Grade 5 expected events  
2 Although an CTEP -AERS  24-hour notificatio n is not required for death clearly related to progressive disease, a full report 
is required as outlined in the table.  
December 15, 2004  
 
Note:  All deaths on study require both routine and  expedited reporting regardless of 
causality.  Attribution to tre atment or other cause must  be provided.  
 
• Expedited AE reporting timelines defined:  
➢ “24 hours; 5 calendar days” – The investigator must initially report the AE via 
CTEP -AERS  within 24 hours  of learning of the event followed by a complete 
CTEP -AERS  report wi thin 5 calendar days  of the initial 24 -hour report.  
➢ “10 calendar days” - A complete CTEP -AERS  report on the AE must be 
submitted within 10 calendar days  of the investigator learning of the event.  
 
• Any medical event equivalent to CTCAE grade 3, 4, or 5 tha t precipitates 
hospitalization (or prolongation of existing hospitalization) must be reported 
regardless of attribution and designation as expected or unexpected with the 
exception of any events identified as protocol -specific expedited adverse event 
repor ting exclusions.   
 
• Any event that results in persistent or significant disabilities/incapacities, 
congenital anomalies, or birth defects must be reported via CTEP -AERS  if the 
event occurs following treatment with an agent under a CTEP IND.  
 
7.4. Use the NCI pr otocol number and the protocol -specific patient ID assigned 
during trial registration on all reports.   Routine Adverse Event Reporting  
All Adverse Events must  be reported in routine study data submissions.  AEs reported 
through CTEP -AERS  must also be repor ted in routine study data submissions.  
 
7.5. Secondary AML/MDS  
A secondary malignancy is a cancer caused by treatment for a previous malignancy 
(e.g., treatment with radiation or chemotherapy). A secondary malignancy is not 
considered a metastasis of the initia l neoplasm. A secondary malignancy is unrelated 
to the first cancer that was treated, and may occur months or even years after initial 
  PhII-107, NCI# 8628  
  8.21.17 v 51 treatment.  
 
CTEP has removed the old AML/MDS forms. Effective August 25, 2010, all secondary 
malignancies that occur foll owing treatment with an agent under an NCI IND/IDE must 
be reported via CTEP -AERS . CTCAE v4.0 has three options available to describe 
treatment -related events:  
 
• Leukemia secondary to oncology chemotherapy  
• Myelodysplastic syndrome  
• Treatment related second ary malignancy  
 
8. PHARMACEUTICAL INFORMATION  
A list of the adverse events and potential risks associated with the investigational or 
commercial agents administered in this study can be found in Section 7.1.  
 
8.1. CTEP -Supplied Investigational  Agent s 
 
8.1.1.  VEGF Trap (N SC 724770 ) 
 
Other Names : Ziv -aflibercept, AVE0005              M.W .: 115 kDa  
 
Classification : Recombinant humanized fusion protein (Chinese hamster ovary 
source).  
 
Description : The fusion protein VEGF Trap is 2 portions of human VEGF 
receptors  
extracellula r domains, VEGFR1 and VEGFR2, fused to the Fc portion of human 
IgG1.  
 
Mode of Action : The cytokine VEGF binds to and activates VEGFR1 and 
VEGFR2 on the vascular endothelium, promoting new vessel formation. VEGF 
Trap is a soluble recombinant decoy receptor that binds and inactivates 
extravacular and hematologic VEGF. It reduces tumor vasculature density, 
available nutrient supply, and tissue matrix components escaping from leaky 
tumor vessels.  
 
How Supplied : VEGF Trap  is supplied by sanofi -aventis Pharmaceut icals and 
distributed by the CTEP, DCTD, NCI.  VEGF Trap is a sterile, nonpyrogenic, 
colorless to pale yellow solution in vials of 200 mg (8 mL) at a concentration of 25 
mg/mL. The solution contains the following excipients:  sucrose, sodium chloride, 
sodium citrate dihydrate, citric acid monohydrate, polysorbate 20, sodium 
phosphate dibasic heptahydrate, sodium phosphate monobasic monohydrate, and 
water for injection. The  pH of VEGF Trap is 6.2. The product is packaged in a type 
1, clear borosilicate glass  vial closed with a flanged cap with tear -off lid and 
  PhII-107, NCI# 8628  
  8.21.17 v 52 inserted sealing disc, Flurotec® (PTFE) coated.  
 
Preparation : Do not shake VEGF Trap.  Withdraw the dose from the vial and 
further  
dilute in 0.9% sodium chloride or 5% dextrose to a final concentration between 
0.6 mg/mL and 8 mg/mL.  
 
Storage : Store intact vials in the refrigerator (2 ° to 8° C). 
 
Stability : Shelf life stability studies of intact vials are ongoing. VEGF Trap’s 
provisional shelf -life is up to 36 months at 2 ° to 8°C. 
 
Caution : VEGF Trap dilu ted to a concentration of 0.6 to 8 mg/mL in 
0.9% NaCl or 5% dextrose is stable for 8 hours at 25°C in infusion 
cassettes or IV bags, or up to 24 hours in the refrigerator.  
 
Route of Administration : Intravenous  
 
Method of Administration : Administered VEGF Trap intravenously over 1 hour 
into a peripheral vein or central venous catheter using an infusion pump; do not 
exceed an infusion duration of 2 hours. VEGF Trap may be administered using 
suitable polyvinyl chloride intravenous delivery devices containing DHEP, 
polyethylene lined PVC, DEHP free PVC containing tris(2 -ethylhexyl)trimellitate 
TOTM; polypropylene, polyurethane, or polybutadiene.  
polyolefin intravenous delivery devices; and/or polyethersulfone filters. The 
infusion  
set must contain a 0.2 micron polyethersulfone inline filter (for example, a low  
protein binding/low drug binding Supor™ Membrane by Pall, or PES membranes 
by 
Millipore).  Polyvinylidene fluoride (PVDF) filters or Nylon filters should not be 
used.  
 
8.1.2.  Agent Ordering  
 
NCI-supplied agents m ay be requested by the Principal Investigator (or their 
authorized designees) at each participating institution. Pharmaceutical 
Management Branch (PMB) policy requires that the agent be shipped directly to 
the institution where the patient is to be treated . PMB does not permit the transfer 
of agents between institutions (unless prior approval from PMB is obtained). The 
CTEP assigned protocol number must be used for ordering all CTEP -supplied 
investigational agents. The responsible investigator at each parti cipating 
institution  
must be registered with CTEP, DCTD through an annual submission of FDA 
form 1572 (Statement of Investigator), Curriculum Vitae, Supplemental 
Investigator Data Form (IDF), and Financial Disclosure Form (FDF). If there are 
several partic ipating investigators at one institution, CTEP -supplied 
  PhII-107, NCI# 8628  
  8.21.17 v 53 investigational agents for the study should be ordered under the name of one lead 
investigator at that institution.  
 
Active CTEP -registered investigators and investigator -designated shipping 
designees  and ordering designees can submit agent requests through the PMB 
Online Agent Order Processing (OAOP) application (https://eapps -
ctep.nci.nih.gov/OAOP/pages/login.jspx).  Access to OAOP requires the 
establishment of a CTEP Identity and Access Management ( IAM) account 
(https://eapps -ctep.nci.nih.gov/iam/) and the maintenance of an “active” account 
status and a “current” password.  For questions about drug orders, transfers, 
returns, or accountability, call (240) 276 -6575 Monday through Friday between 
8:30 a m and 4:30 pm (ET) or email PMBAfterHours@mail.nih.gov anytime.  
 
8.1.3.  Agent Accountability  
 
Agent Inventory Records – The investigator, or a responsible party designated by 
the investigator, must maintain a careful record of the inventory and disposition of 
all agents received from DCTD using the NCI Drug Accountability Record Form 
(DARF). See the NCI Investigator’s Handbook for Procedures for Drug 
Accountability and Storage.  
 
8.2. Commercial Agents  
 
8.2.1.  Interleukin -2 
 
Other Names :  Aldesleukin, IL -2, rlL -2, T-cell growt h factor  
 
Classification :  Biological response modifier  
 
Mode of Action :  Endogenous substance secreted by OK -T4 cells and 
lymphocytes. Enhances primary and secondary cytotoxic T -cell responses, causes 
T-cell mitogenesis and proliferation, and enhances non -killer cell activity.  
 
Storage and Stability :  Intact vials are stored in the refrigerator (2 -8°C) with 
protection from light. Each vial bears an expiration date.  
 
Reconstituted IL -2 should be further diluted with 5% Dextrose, USP. It is not to be 
mixed w ith saline -containing solutions. Reconstituted IL -2 may be diluted as 
necessary in volumes of 50 ml to 500 ml with 5% Dextrose, USP plus 0.1% 
Albumin Human, USP. When diluting, the Albumin Human, USP should be added 
to the 5% Dextrose Injection, USP prior to the addition of the IL -2. When diluted 
for IV administration in 5% Dextrose Injection, USP, a plastic bag (e.g., Viaflex, 
manufactured by Travenol Laboratories, Inc.) containing 0.1% Albumin Human. 
IL-2 is chemically stable for 48 hours at refrigerated and room temperatures, 2 -
30°C.  
  PhII-107, NCI# 8628  
  8.21.17 v 54  
Dose Specifics :  Interleukin -2 600,000 MIU/kg/dose or 720,000 MIU/kg/dose over 
15 minute IV infusion every 8 hours on Days 1 -5 of each cycle for a maximum of 
14 doses. For the purpose of this study, interleukin -2 will be giv en at 600,000 
MIU/kg.  
 
Preparation : Aseptically inject 1.2 ml of sterile water for injection into the vial to 
dissolve the lyophilized cake. Since contents of the vial are under vacuum, the 
diluent should be directed against the sides of the vial to avoid excess foaming. 
Remove flip -off plastic cap and swab the target area of the stopper with antiseptic.  
 
Administration :  For sterility considerations, the reconstituted IL -2 should be 
administered immediately or held at 2 -8°C for up to 12 hours in 1.2 ml of sterile 
water for injection, and is stable for at least 24 hours at room temperature.  
 
Incompatibilities :  Incompatible with normal saline (results in a precipitate). It 
should not be mixed with anything except D5W and sterile water.  
 
Availability :  IL-2 is a FDA approved therapy for melanoma and is commercially 
available.  
 
Toxicity :  See section 7.1.2.  
 
  For more information please refer to the drug’s package insert.  
 
9. CORRELATIVE/SPECIAL STUDIES  
9.1. Laboratory Correlative Studies  
All patients participating in  the study must undergo correlatives studies.  Laboratory 
correlates will include the following:  
 
• Evaluate baseline serum VEGF level as a predictor for response to this combination 
regimen to compare the response rates and survival rates between high ( greater 
than 125 pg/ml) and low baseline serum VEGF.  
• Measurement of baseline VEGFR2 prior to therapy.  
• Measuring VEGF levels prior to and at completion of IL -2 to measure if VEGF 
remained low throughout the 5 days that IL -2 is administrated.  
 
In addition to the se studies listed above, other correlatives studies may be done , 
utilizing research samples collected on this study, that will primarily focus on 
biomarkers of prognosis or prediction of therapeutic benefit based on current or future 
scientific evidence.  
 
9.1.1.  Collection of Specimens  
Blood specimens  will be collected for the purpose of laboratory corollary studies 
as follows:  
  PhII-107, NCI# 8628  
  8.21.17 v 55  
Table. Blood sample Collection  
Course 1  Red Top 
Tubes5 Green Top 
Tubes6 PAX 
tubes7 Yellow 
Top 
Tube8 
Baseline1 3 10 1 1 
Cycle 1 of IL -2, Day 12 1 none  none  none  
Cycle 1 of IL -2, the day 
after the last dose of IL -2 1 none  none  none  
Cycle 2 of IL -2, Day 13  1 none  none  none  
Cycle 2 of IL -2, the day 
after the last dose of IL -2 3 10 1 none  
Course 2/3     none  
Week 14 1 none  none  none  
Cycle 2 of IL -2, the day 
after the last dose of IL -2 3 10 1 none  
Month 12  3 10 1 none  
Progression  3 10 1 none  
1. Baseline: within 72 hours of the first dose of aflibercept (Arm A)  or IL -2 (Arm B) . 
2. Cycle 1 of IL -2, Day 1: before both the dose aflibercept and  the first dose of IL -2 
given on that day . This applies to Arm A only. For Arm B, this time point is not 
required.  
3. Cycle 2 of IL -2, Day 1: before both the dose aflibercept and the first dose of IL -2 
given on that day  (Arm A) or the first dose of IL -2 (Arm B). 
4. Course 2/3, week 1, before the first dose of Aflibercept  for arm A  and the first dose 
of IL -2 for arm B  
5. 10 cc RED top tubes (BDcat #367820 or SST 367988 gel separator/gold top/ tiger 
tubes if the center can centrifuge them)  
6. 10 cc GREEN top tubes (BD c at # 366480)  
7. PAX tube (Fisher #23 021 01)  
8. 10 cc YELLOW top tube. (BD cat # 364606)  
 
Transfer or, if applicable, ship blood samples by overnight courier Monday -
Thursday only to:  
 
Immunologic Monitoring and Cellular Products Laboratory  
University of Pittsbu rgh Cancer Institute  
UPCI -IMCPL, Suite 1.26  
Study Coordinator  
Hillman Cancer Center  
5117 Centre Avenue  
Pittsburgh, PA 15213  
Tel: (412) 624 -0078  
FAX: (412) 623 -6625  
 
  PhII-107, NCI# 8628  
  8.21.17 v 56 Please submit the Specimen Submission Form (Appendix D) for each sample 
sent.  
 
Notify the IMCPL study coordinator by fax (412 -623-6625) when the samples are 
shipped. If you are unable to get through to the laboratory by fax, telephone the 
study coordinator and provide the tracking number.  
 
The IMCPL is the Immunology Core Laboratory for ECOG an d has a great deal of 
experience in shipment and handling of blood, tumor and lymph node samples. The 
IMCPL provides contact information and a fax request form to the sites, and when 
a patient is scheduled, a tissue sample kit is shipped (generally via gro und) to the 
site, containing all necessary blood tubes, tumor containers (containing sterile 
medium) sample instructions as well as return overnight shipping instructions. 
Upon receipt in the laboratory, the blood and tissue samples are logged in a 
process ed according to the protocol -specific SOPs. Samples which are 
compromised (hemolyzed or which arrived more than 48 hours after 
draw/isolation) are discarded (currently less than 2% of >750 samples which arrive 
at the laboratory annually from ECOG sites).  
 
Pathology Specimen Submissions for Banking for Research Studies  (at baseline, 
then at disease progression) : 
• Primary Melanoma (for patients with known primary cutaneous melanoma)  
Fifteen (15) unstained slides preferably from the thickest portion of the tum or 
for immunostains (please do not deparaffinise slides) OR, if the primary 
pathologist is willing, please request the corresponding block, which will be 
promptly returned upon request.  If the patient has more than one primary 
lesion, please include above  slides and/or block for each primary.  
• Resected in -transit or satellite metastases, or cutaneous metastases, or lymph 
node metastases, or lung metastases  
Fifteen to twenty (15 -20) unstained slides from the thickest part of the tumor 
or, if the primary path ologist is willing, please request the corresponding block, 
which will be promptly returned upon request.  
NOTE:   Please provide a surgical pathology report to accompany the slides.  
• Progression/Relapse Biopsy (if performed, for banking for future research )  
Fifteen to twenty (15 -20) unstained slides from the thickest part of the tumor 
or, if the primary pathologist is willing, please request the corresponding block, 
which will be promptly returned upon request.  
 
 Please transfer or, if applicable, ship to  the IMCPL, as noted above. For shipping, 
regular mail may be used for these tissue samples  OR these may be included in the 
same package with the blood samples shipped by overnight courier . Also please 
notify the IMCPL study coordinator as noted above.  
 
  PhII-107, NCI# 8628  
  8.21.17 v 57 9.1.2.  VEGF  and VEGF R2 Testing  
 
   VEGF levels will be tested in serum collected at the following time points:  
• Course 1:  
o Baseline: before the first dose of aflibercept (within 72 hours of the first 
dose of aflibercept)  or IL -2 for Arm B patients .  
o Cycle 1 of IL -2, Day 1: before both the dose aflibercept  (Arm A) and the 
first dose of IL -2 given on that day.  This applies to arm A only and not 
required for Arm B.  
o Cycle 1 of IL -2, the day after the last dose of IL -2 (Arms A and B) . 
o Cycle 2 of IL -2, Day 1: before both  the dose aflibercept (Arm A) and the 
first dose of IL -2 given on that day  (Arms A and B) . 
o Cycle 2  of IL -2, the day after the last dose of IL -2 (Arms A and B) . 
• Courses 2 and 3 : 
o  Week 1 : before the f irst dose aflibercept  for Arm A  and the first dose of 
IL-2 for Arm B . 
o Cycle 2 of IL -2, the day after the last dose of IL -2 (Arms A and B)  
• Month 12  
• Progression  
VEGF R2 levels will be tested only at baseline  in both arms . 
 
The standardized R&D Systems ELISA kits for measurement of both VEGF and 
VEGF -R2. These will be done at the University of Pittsburgh Cancer Institute 
Immune Monitoring Laboratory (IML).  The IMCPL participates in national quality 
control and comparison surveys and is inspected and accredited by the College of 
American Pathologists (CAP).   It is li censed by DHHS to receive specimens from out -
of-state locations (CLIA ID# 39D0657004).   The IML is also licensed by the state of 
Pennsylvania and is inspected by the Pennsylvania Department of Health.   The CPL 
is registered with FDA (#3004571535) for somat ic cell culture and tissue 
processing.   It also has a Master File (BB -MF-12244) for the facility operation with 
FDA.  
 
9.1.3.  Banking of Specimens for Future Laboratory Corollary Studies  
 
Specimens will be banked at the IMCPL and additional laboratory corollary st udies 
will  be conducted  based on the availability of specimens and funding.  
 
9.2.     Anti -VEGF Trap Antibody Testing  
 
If a patient experiences a hypersensitivity or infusion reaction to aflibercept, serum 
should be obtained to evaluate for a nti-aflibercept an tibody formation at the time 
of the reaction.  At the time of the reaction , whole blood will be collected in red -top 
  PhII-107, NCI# 8628  
  8.21.17 v 58 vacutainer tubes (containing no additives or anti -coagulant) for serum preparation 
using the procedures outlined below. (Schematic diagrams of sample labeling and 
collection procedures are provided in Appendices F and G).   
 
9.2.1.  Serum Sample Collection and Preparation  
 
1. Sample collection: Collect 5 mL of blood in one red top tube (B -D Cat #367814 
Hemogard, 5mL plastic tubes with silica clot activat or) for each Anti -
Aflibercept Antibody sample.  
2. Immediately mix by inverting tube at least once.  
3. Allow serum to clot for 30 minutes.  
4. Centrifuge at 1200 x g for 15 minutes to separate clot from serum.  
5. Within 30 minutes after centrifugation draw off serum  very slowly with transfer 
pipette, approaching no closer than 0.5cm of the buffy coat and taking great 
care not to disturb the buffy coat (any contamination may invalidate the assay).  
6. Labels are provided by Regeneron for each specimen. Complete copy with  the 
patient’s subject identification number. Place one label on the cryovial (see 
Appendix F for diagrammatic instructions on label placement) and the second 
copy on the Sample Shipping Log before transferring the patient sample. Note: 
for duplicate sampl es, repeat the labeling step  
7. Preparation of serum samples for Anti -Aflibercept  antibody : Aliquot serum 
specimen equally into TWO plastic cryovials, one for the primary and one for 
the duplicate sample. Do NOT exceed 1.5mL of serum into each cryovial; 
acceptable cryovials are VWR #14224 -374 or Corning #430659.  
8. Freeze all cryovials as soon as possible. All specimens must be stored frozen at 
-20° C (or colder) in a freezer that is NOT frost -free, until shipped to the 
laboratory at Regeneron Pharmaceuticals, Inc. Note: The Sample Freezer 
Temperature Log must be completed daily.  
 
9.2.2.  Serum Sample Shipping  
 
1. Complete the appropriate information for each blood draw on the Sample 
Shipping Log. Include: subject identification number, and date and  time of 
specimen coll ection, etc. The original Sample Shipping Log should be kept in the 
Sample Shipping Log Binder. The Sample Shipping Log pages have been pre -
numbered. Use one form per shipment. Begin a new form with each new shipment.  
 
2. Include a copy of the Sample Ship ping Log with the shipment and send to 
Regeneron Pharmaceuticals, Inc. at the address below:  
 
Sample Management  
Regeneron Pharmaceuticals, Inc.  
767 Old Saw Mill River Road  
Tarrytown, NY 10591  
 
  PhII-107, NCI# 8628  
  8.21.17 v 59 3. The original Sample Shipping Log should be kept in the Samp le Shipping Log 
Binder.  
4. Only the primary samples of each patient should be sent with the first 
shipment. This is to ensure that, in case of damage during shipment, there is one 
sample per subject at the site for the backup. Duplicate samples should be 
shipped on alternate shipping dates. Please refer to the Shipping Calendar for 
dates.  
5. Samples should be shipped Monday or Tuesday only.  
6. Sufficient dry ice is to be included for samples to remain frozen for at least 48 
hours (we recommend 14 lbs. of  dry ice).  
7. On the date you will be shipping specimens, please notify Sample Management 
at Regeneron Pharmaceuticals, Inc. to expect arrival of the box ( 914) 345 -7644 . 
Please also fax a copy of the shipping list and FedEx package tracking number 
to Samp le Management at Regeneron Pharmaceuticals, Inc. at (914) -593-1024.  
8. Please note that for all shipments you must access the FedEx Ship Manager at 
www.fedex.com to prepare shipments online. The FedEx Ship Manager provides 
access to Regeneron's Federal Ex press account for direct billing purposes. 
Prepared shipments that do not utilize the FedEx Ship Manager will NOT 
be reimbursed. Refer to the FedEx shipping requirements in your Sample 
Shipping Log Binder for instructions on shipping the samples.  
 
Note: I t is the Investigator’s Responsibility to ensure that all shipments of 
hazardous/dangerous goods comply with current DOT/IATA regulations.  
 
 
  PhII-107, NCI# 8628  
  8.21.17 v 60 10. STUDY CALENDAR  
These study calendars apply to arm A only. For Arm B (HD IL -2 alone), there are no protocol 
specifi c requirements. Study investigators should follow the local institutional standard of care 
guidelines for safety monitoring and safety laboratory testing on Arm B. Baseline evaluations are 
to be conducted within 2 weeks  prior to administration of protocol therapy  on both study arms , 
unless indicated otherwise, elsewhere in the protocol .  Scans and X -rays must be done not more 
than
 28 days prior to the start of therapy  on both study arms .  In the event that the patient’s 
condition is deteriorating, laborator y evaluations should be repeated within 48 hours prior to 
initiation of the next cycle of therapy.  
 
 
Course 1  (Arm A)  Pre-
Study  Wk 
1 Wk 
2 Wk 
3 Wk 
 4 Wk 
5 Wk 
6 Wk 
7 Wk 
8 Wk 
9 Wk 
10 
Aflibercepta  
  
X  
  
X  
  
X  
  
X  
  
X  
 
Interleukin -2a     
X   
X      
 
Informed consent   
X  
  
  
  
  
  
  
  
  
  
 
 
Demographics   
X  
  
  
  
  
  
  
  
  
  
 
 
Medical history   
X  
  
  
  
  
  
  
  
  
  
 
 
Concurrent meds   
X     X---------------------------------------------------------------------------- X 
 
Physical exam   
X  
X  
  
X  
  
X  
  
X  
  
X  
 
 
Vital signs   
X  
X  
  
X  
  
X  
  
X  
  
X  
 
 
Blood pressureh  
X  
X  
X  
X     
X   
X   
X  
 
Height   
X  
  
  
  
  
  
  
  
  
  
 
 
Weight   
X  
X  
  
X  
  
X  
  
X  
  
X  
 
 
Performance status   
X  
X  
  
X  
  
X  
  
X  
  
X  
 
 
CBC w/diff, plts  
Urinalysis and  UPCRb  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
 
Serum chemistryc  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X 
 
PT/INR   
X           
 
Echocardiogram   
X  
  
  
  
  
  
  
  
  
  
X 
Cardiac stress test , ECGd  
X           
PFTse  
X           
 
Adverse event evaluation      X ------------------- --------------------------------------------------------- X 
 
Tumor measurements  X  
  
  
  
  
  
  
  
  
 X 
 
Radiologic evaluationf  
X  
  
  
  
  
  
  
  
  
  
X 
 
B-HCGg  
X  
  
  
  
  
  
  
  
  
  
 
a:   Aflibercept: IV Day 1 14 -day cycle. IL -2: 600,000 U/kg/dose IV Q8h x 5 days (max 14 doses) starting on day 1 
of weeks 3 and 5. An IL -2 cycle may be delayed until the resolution of limiting toxicities.  
b:    Spot urine for protein and creatinine must be obtained to calculate urine protein:creatinine ratio (UPCR). A 24 -
hour urine collection for quantitative protein determination must be obtained for a UPCR >1.  
  PhII-107, NCI# 8628  
  8.21.17 v 61 c:   Albumin, alkaline phosphatase, total bilirubin, bicarbonate, BUN, calcium, chloride, creatinine, glucose, LDH, 
phosphorus, potassium, total protein, SGOT[AST], S GPT[ALT], sodium.  
d:    Patients who are over 40 years old or have had previous myocardial infarction greater than 6 months prior to 
study entry or have significant cardiac family history (CAD or serious arrhythmias) will be required to have a 
negative or low probability cardiac stress test (thallium stress test, stress MUGA or exercise stress test) for cardiac 
ischemia within 8 weeks prior to registration.  Patients who are not required to have a cardiac stress test should 
have an electrocardiogram at basel ine to be reviewed by the treating physician investigator. Patients who undergo 
echocardiography as part of their cardiac stress test are not required to have a separate baseline echocardiogram.  
e:    Pulmonary function tests (PFTs) are required for patien ts over 50 years old or with significant pulmonary or 
smoking history.   PFTs may be done up to 4 weeks prior to registration.  
f:     Radiologic evaluation should include MRI or contrast CT of the brain.  
g:    Serum pregnancy test (women of childbearing pot ential).  
h:    blood pressure will be checked weekly during the first cycle of aflibercept, then every two weeks while on study.  
However, at the initiation of the maintenance phase, if aflibercept is started at a higher dose than in the 
combination phase, blood pressure monitoring should be done weekly for the first 3 weeks of the maintenance 
phase to ensure tolerance of the higher aflibercept dose. This is the minimum blood pressure monitoring required. 
Appendix H includes a patient diary that includes mor e frequent blood pressure monitoring and can be used at 
the discretion of the treating physician.   
 
 
 
 
Course 2/3  (Arm A)  Maintenance 
aflibercept  
 
Course 2/3, and  
Maintenance aflibercept  Wk 
1 Wk 
2 Wk 
3 Wk 
 4 Wk 
5 Wk 
6 Wk 
7 Wk 
8  Off 
Studye 
Aflibercepta   
X  
  
X  
  
X  
  
X  
  
X  
 
Interleukin -2a  
X   
X        
 
Concurrent meds      X------------------------------------------------------------------------ X  
 
Physical exam   
X  
  
X  
  
X  
  
X  
  
X (q 2wks)   
X 
 
Vital signs and blood pressure   
X  
  
X  
  
X  
  
X  
  
X (q 2wks)   
X 
 
Weight   
X  
  
X  
  
X  
  
X  
  
X (q 2wks)   
X 
 
Performance status   
X  
  
X  
  
X  
  
X  
  
X (q 2wks)   
X 
 
CBC w/diff, plts  
Urinalysis and  UPCRb  
X  
X  
X  
X  
X  
X  
X  
X  
X X 
 
Serum chemistryc  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X 
 
Echocardiogram   
  
  
  
  
  
  
  
X  
  
 
 
Adverse event evaluation     X ------------------------------------------------------------------------- X X 
 
Tumor measurements   
  
  
  
  
  
  
 X 
 X 
 X 
Radiologic evaluationd        X X X 
 
a:   Aflibercept: IV Day 1 of a14 -day cycle. I L-2: 600,000 U/kg/dose IV Q8h x 5 days (max 14 doses) starting on day 
1 of weeks 3 and 5. An IL -2 cycle may be delayed until the resolution of limiting toxicities. During the maintenance 
aflibercept phase, aflibercept monotherapy will be initiated to be ad ministered IV on Day 1of each 14 -day cycle.  
In the absence of limiting toxicities, aflibercept will be given at 4 mg/kg in the maintenance phase. In this case, 
blood pressure monitoring should be done weekly for the first 3 weeks of the maintenance phase t o ensure tolerance 
of the higher aflibercept dose. However, if the aflibercept dose had to be reduced during the combination phase due 
to aflibercept -related toxicities, then that reduced dose will be used for maintenance therapy. No need for weekly 
monito ring of blood pressure, if the reduced dose has already been demonstrated to be tolerable.   
b:  Spot urine for protein and creatinine must be obtained to calculate urine protein:creatinine ratio (UPCR). A 24 -hour 
urine collection for quantitative protein determination must be obtained for a UPCR >1. During the maintenance 
aflibercept phase, this is to be done every 2 weeks.  
c:   Albumin, alkaline phosphatase, total bilirubin, bicarbonate, BUN, calcium, chloride, creatinine, glucose, LDH, 
phosphorus, potass ium, total protein, SGOT[AST], SGPT[ALT], sodium. During the maintenance aflibercept 
phase, this is to be done every 2 weeks.  
  PhII-107, NCI# 8628  
  8.21.17 v 62 d: Radiologic evaluation should include MRI or contrast CT of the brain. During the maintenance aflibercept phase  
tumor radiologic  evaluation and tumor measurements will take place every  12 weeks ( -/+1 week) for the first 2 
years , then every 6 months ( -/+ 2 weeks) for years 3 -5, then yearly ( -/+ 4 weeks) afterwards . 
e: off study evaluation.  Patients will be followed for 5 years afte r removal from study or until death, whichever occurs 
first. The frequency and the type of evaluations during this follow up period will follow institutional standard of 
care practices. For patients who wish not to follow with a study investigator, they ca n be followed by their treating 
physician of choice and also following local standard of care practices. Data on disease progression and survival 
will be collected on all patients every 3 -4 months.  
 
 
For the purposes of this study, patients should be ree valuated for response at the end of course 1 
(10 weeks -/+ 1 week for Arm A and 8 weeks -/+ 1 week for Arm B) and at the end of every 
course thereafter (8 weeks -/+ 1 week).  It will be done every 12 weeks -/+ 1 week during the 
maintenance Aflibercept Mono therapy phase (Arm A) or observation phase (for arm B)  for the 
first 2 years , then every 6 months ( -/+ 2 weeks) for years 3 -5, then yearly ( -/+ 4 weeks) 
afterwards . Radiologic evaluation should include MRI or contrast CT of the brain on both study 
arms (A and B).  
Off study evaluation for Arm B: Patients will be followed for 5 years after removal from study or 
until death, whichever occurs first. The frequency and the type of evaluations during this follow 
up period will follow institutional standard of care  practices. For patients who wish not to follow 
with a study investigator, they can be followed by their treating physician of choice and also 
following local standard of care practices. Data on disease progression and survival will be 
collected on all pat ients every 3 -4 months.   
  PhII-107, NCI# 8628  
  8.21.17 v 63 11. MEASUREMENT OF EFFECT  
11.1. Antitumor Effect – Solid Tumors  
For the purposes of this study, patients should be reevaluated for response at the end of 
course 1  (10 weeks  -/+ 1 week  for Arm A and 8 weeks -/+ 1 week for Arm B ) and at 
the end of every course thereafter (8 weeks  -/+ 1 week ).  It will be done every 12 weeks 
-/+ 1 week during the maintenance Aflibercept Monotherapy phase  (Arm A) or 
observation phase ( for arm B)  for the  first 2 years , then every 6 months ( -/+ 2 weeks) 
for years 3-5, then yearly ( -/+ 4 weeks) afterwards . Radiologic evaluation should 
include MRI or contrast CT of the brain on both study arms (A and B). In addition to a 
baseline scan, confirmatory scans should also be obtained not less than 4  weeks 
following initial  documentation of objective response.  
 
Response and progression will be evaluated in this study using the new international 
criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) 
Committee , version 1.1 [Eur J Cancer, 2009. 45(2): p. 228-47.].  Changes in only the 
largest diameter (unidimensional measurement) of the tumor lesions are used in the 
RECIST criteria.  
 
11.1.1.  Definitions  
 
Evaluable for toxicity .  All patients will be evaluable for toxicity from the time of 
their first  protocol  drug administration . 
 
Evaluable for objective response.   Only those patients who have measurable disease 
present at baseline, have received at least course 1  of therapy, and have had their 
disease re -evaluated will be considered evaluable for response.  These patients will 
have their response classified according to the definitions stated below.  (Note:  
Patients who exhibit objective disease progression prior to the end of course  1 will 
also be considered evaluable.)  
 
NOTE:  Since we hypothesize that reducing V EGF will improve response to IL -2, 
a patient must complete course 1 ( at least one cycle of VEGF Trap + 2 cycles of 
IL-2) in order to be evaluable for response.  
 
11.1.2.  Disease Parameters  
 
Measurable disease .  Measurable lesions are defined as those that can be ac curately 
measured in at least one dimension (longest diameter to be recorded) as >20 mm 
with conventional techniques (CT, MRI, x -ray) or as >10 mm with spiral CT scan.  
All tumor measurements must be recorded in millimeters  (or decimal fractions of 
centime ters).  
 
Note:  Tumor lesions that are situated in a previously irradiated area might or might 
not be considered measurable.  
 
  PhII-107, NCI# 8628  
  8.21.17 v 64 Non-measurable disease .  All other lesions (or sites of disease), including small 
lesions (longest diameter <20 mm with convention al techniques or <10 mm using 
spiral CT scan), are considered non -measurable disease.  Bone lesions, 
leptomeningeal disease, ascites, pleural/pericardial effusions, lymphangitis 
cutis/pulmonis, inflammatory breast disease, abdominal masses (not followed by  
CT or MRI), and cystic lesions are all non -measurable.  
 
Target lesions.   All measurable lesions up to a maximum of 5 lesions per organ and 
10 lesions in total, representative of all involved organs, should be identified as 
target lesions  and recorded and measured at baseline.  Target lesions should be 
selected on the basis of their size (lesions with the longest diameter) and their 
suitability for accurate repeated measurements (either by imaging techniques or 
clinically).  A sum of the longest diameter (L D) for all target lesions will be 
calculated and reported as the baseline sum LD.  The baseline sum LD will be used 
as reference by which to characterize the objective tumor response.  
 
Non-target lesions .  All other lesions (or sites of disease) including any measurable 
lesions over and above the 10 target lesions should be identified as non-target 
lesions and should also be recorded at baseline.  Measurements of these lesions are 
not required, but the presence or absence of each should be noted throughout 
follow -up.  
 
11.1.3.  Methods for Evaluation of Measurable Disease  
 
All measurements should be taken and recorded in metric notation using a ruler or 
calipers.  All baseline evaluations should be performed as closely as possible to the 
beginning of treatment and ne ver more than 4 weeks before the beginning of the 
treatment.  
 
The same method of assessment and the same technique should be used to 
characterize each identified and reported lesion at baseline and during follow -up. 
Imaging -based evaluation is preferred to  evaluation by clinical examination when 
both methods have been used to assess the antitumor effect of a treatment.  
 
Clinical lesions   Clinical lesions will only be considered measurable when they are 
superficial (e.g., skin nodules and palpable lymph node s).  In the case of skin 
lesions, documentation by color photography, including a ruler to estimate the size 
of the lesion, is recommended.  
 
Chest x -ray  Lesions on chest x -ray are acceptable as measurable lesions when they 
are clearly defined and surroun ded by aerated lung.  However, CT is preferable.  
 
Conventional CT and MRI   These techniques should be performed with cuts of 10 
mm or less in slice thickness contiguously.  Spiral CT should be performed using a 
5 mm contiguous reconstruction algorithm.  T his applies to tumors of the chest, 
abdomen, and pelvis.  Head and neck tumors and those of extremities usually 
require specific protocols.  
  PhII-107, NCI# 8628  
  8.21.17 v 65  
Ultrasound (US)   When the primary endpoint of the study is objective response 
evaluation, US should not be used to measure tumor lesions.  It is, however, a 
possible alternative to clinical measurements of superficial palpable lymph nodes, 
subcutaneous lesions, and thyroid nodules.  US might also be useful to confirm the 
complete disappearance of superficial lesions us ually assessed by clinical 
examination.  
 
Endoscopy, Laparoscopy   The utilization of these techniques for objective tumor 
evaluation has not yet been fully and widely validated.  Their uses in this specific 
context require sophisticated equipment and a high  level of expertise that may only 
be available in some centers.  Therefore, the utilization of such techniques for 
objective tumor response should be restricted to validation purposes in reference 
centers. However, such techniques may be useful to confirm complete pathological 
response when biopsies are obtained.  
 
Tumor markers   Tumor markers alone cannot be used to assess response.  If markers 
are initially above the upper normal limit, they must normalize for a patient to be 
considered in complete clinica l response.  Specific additional criteria for 
standardized usage of prostate -specific antigen (PSA) and CA -125 response in 
support of clinical trials are being developed.  
 
Cytology, Histology   These techniques can be used to differentiate between partial 
responses (PR) and complete responses (CR) in rare cases (e.g., residual lesions in 
tumor types, such as germ cell tumors, where known residual benign tumors can 
remain).  
 
The cytological confirmation of the neoplastic origin of any effusion that appears 
or worsens during treatment when the measurable tumor has met criteria for 
response or stable disease is mandatory to differentiate between response or stable 
disease (an effusion may be a side effect of the treatment) and progressive disease.  
 
11.1.4.  Response Crit eria 
 
11.1.4.1.  Evaluation of Target Lesions  
 
Complete Response (CR) :Disappearance of all target lesions  
 
Partial Response (PR) : At least a 30% decrease in the sum of the 
longest diameter (LD) of target lesions, 
taking as reference the baseline sum LD  
 
Progressive Disease (PD) : At least a 20% increase in the sum of the LD 
of target lesions, taking as reference the 
smallest sum LD recorded since the treatment 
started or the appearance of one or more new 
  PhII-107, NCI# 8628  
  8.21.17 v 66 lesions  
Stable Disease (SD) : Neither sufficient shrinkage to qu alify for PR 
nor sufficient increase to qualify for PD, 
taking as reference the smallest sum LD since 
the treatment started  
 
11.1.4.2.  Evaluation of Non -Target Lesions  
 
Complete Response (CR) : Disappearance of all non -target lesions and 
normalization of tumor marker  level  
 
Note:  If tumor markers are initially above the 
upper normal limit, they must normalize for 
a patient to be considered in complete clinical 
response.  
 
Incomplete Response/  
Stable Disease (SD) : Persistence of one or more non -target 
lesion(s) and/or maintenance of tumor 
marker level above the normal limits  
 
Progressive Disease (PD) : Appearance of one or more new lesions 
and/or unequivocal progression of existing 
non-target lesions  
 
Although a clear progression of “non -target” lesions only is exception al, the 
opinion of the treating physician should prevail in such circumstances, and 
the progression status should be confirmed at a later time by the review 
panel (or Principal Investigator).  
 
11.1.4.3.  Evaluation of Best Overall Response  
 
The best overall response is the best response recorded from the start of the 
treatment until disease progression/recurrence (taking as reference for 
progressive disease the smallest measurements recorded since the treatment 
started).  The patient's best response assignment will de pend on the 
achievement of both measurement and confirmation criteria  
 
Target 
Lesions  Non-Target 
Lesions  New 
Lesions  Overall 
Response  Best Response for this 
Category Also Requires:  
CR CR No CR >4 wks. confirmation  
CR Non-
CR/Non -PD No PR  
>4 wks. confirma tion 
PR Non-PD No PR 
SD Non-PD No SD documented at least once 
>4 wks. from baseline  
PD Any Yes or No  PD  
no prior SD, PR or CR  Any PD* Yes or No  PD 
  PhII-107, NCI# 8628  
  8.21.17 v 67 Any Any Yes PD 
* In exceptional circumstances, unequivocal progression in non -target lesions may be  
accepted as disease progression.  
 
Note : Patients with a global deterioration of health status requiring discontinuation of 
treatment without objective evidence of disease progression at that time should be 
reported as “ symptomatic deterioration” .  Every e ffort should be made to document 
the objective progression even after discontinuation of treatment.  
 
 
11.1.5.  Duration of Response  
 
Duration of overall response :  The duration of overall response is measured from 
the time measurement criteria are met for CR or PR  (whichever is first recorded) 
until the first date that recurrent or progressive disease is objectively documented 
(taking as reference for progressive disease the smallest measurements recorded 
since the treatment started).  
 
The duration of overall CR is  measured from the time measurement criteria are first 
met for CR until the first date that recurrent disease is objectively documented . 
 
Duration of stable disease :  Stable disease is measured from the start of the 
treatment until the criteria for progres sion are met, taking as reference the smallest 
measurements recorded since the treatment started.  
 
11.1.6.  Progression -Free Survival  
 
PFS is defined as the duration of time from start of treatment to time of progression  
(or death if there is no progression date) . Patients with neither a progression date 
nor date of death will be censored as of last contact.  
 
12. DATA REPORTING / REGULATORY REQUIREMENTS  
Adverse event lists, guidelines, and instructions for AE reporting can be found in Section 
7.0 (Adverse Events: List and Reporting Requirements).  
 
12.1. Data Reporting  
 
12.1.1.  Method  
 
This study will be monitored by the Clinical Data Update System (CDUS) version 
3.0.  Cumulative CDUS data will be submitted quarterly to CTEP by electronic 
means.  Reports are due January 31, April 30, July 31, and October 31.  Instructions 
for submitting data using the CDUS can be found on the CTEP web site 
(http://ctep.cancer.gov ).  Note :  All adverse events that have occurred on the study, 
including those reported through CTEP -AERS , must be reported via CDUS.  
 
12.1.2.  Responsibility for Data Submission  
  PhII-107, NCI# 8628  
  8.21.17 v 68  
Study participants are responsible for submitting CDUS data and/or data forms to 
the 
  Coordinating Center quarterly by  January 31, April 30, July 31, and October 31  to 
allow time for Coordinating Center compilation, Principal Investigator review, and 
timely submission to CTEP (see Section 12.1.1.).  For trials monitored by CTMS, 
the quarterly data submission to CTEP from provided by Theradex should be 
copied to the Coordin ating Center.  
 
  The Coordinating Center is responsible for compiling and submitting CDUS data 
to CTEP for all participants and for providing the data to the Principal Investigator 
for review.   
 
12.1.3.  Data Collection Forms and Submission Schedule  
 
All data will  be collected using COH data collection forms via an electronic data 
capture system.  Any original data collection forms will reside at the originating 
institutions in secure location.  
 
ELIGIBILITY CHECKLIST :  The data manager at the registering site will have 
completed and faxed this form at the time of registration.  
ON-STUDY FORM (FORM OS) :  Completed on -study forms due within two 
weeks of registration.  
TREATMENT FORM (FORM RX) :  Completed treatment forms are due within 
four weeks of completion of a cycl e.  
ADVERSE EVENT COLLECTION :  Completed adverse events collection form 
due within four weeks of completion of a cycle.  
FLOW SHEETS :  Protocol specific flow sheets are to be submitted along with 
each treatment form.  
RESPONSE/OFF -STUDY/FOLLOW -UP:  Form F/U is to be submitted each 
time a patient is evaluated for response and/or new follow -up information is 
obtained.  
SUPPLEMENTAL DATA FORM : The timeline for submission of the 
supplemental data form will be protocol specific, if applicable.  
 
12.2. CTEP Multicenter Gu idelines  
This protocol will adhere to the policies and requirements of the CTEP Multicenter 
Guidelines.  The specific responsibilities of the Principal Investigator and the 
Coordinating Center (Study Coordinator) and the procedures for auditing are present ed 
in Appendix B.  
 
• The Principal Investigator/Coordinating Center is responsible for distributing 
all IND Action Letters or Safety Reports received from CTEP to all 
participating institutions for submission to their individual IRBs for action as 
required.  
 
  PhII-107, NCI# 8628  
  8.21.17 v 69 • Except in very unusual circumstances, each participating institution will order 
DCTD -supplied agents directly from CTEP.  Agents may be ordered by a 
participating site only after the initial IRB approval for the site has been 
forwarded by the Coordinating  Center to the CTEP PIO  
(PIO@ctep.nci.nih.gov ) (except for Group studies) . 
 
12.3. Cooperative Research and Development Agreement (CRADA)/Clinical Trials 
Agreement (CTA)  
The agent(s) supplied by CTEP, DCTD, NCI used in  this protocol is/are provided to 
the NCI under a Collaborative Agreement (CRADA, CTA, CSA) between the 
Pharmaceutical Company(ies) (hereinafter referred to as Collaborator(s)) and the NCI 
Division of Cancer Treatment and Diagnosis.  Therefore, the followi ng 
obligations/guidelines, in addition to the provisions in the Intellectual Property Option 
to Collaborator (http:// ctep.cancer.gov/industry) contained within the terms of award, 
apply to the use of the Agent(s) in this study:  
 
1. Agent(s) may not be use d for any purpose outside the scope of this protocol, nor 
can Agent(s) be transferred or licensed to any party not participating in the clinical 
study.  Collaborator(s) data for Agent(s) are confidential and proprietary to 
Collaborator(s) and shall be main tained as such by the investigators.  The protocol 
documents for studies utilizing investigational Agents contain confidential 
information and should not be shared or distributed without the permission of the 
NCI.  If a copy of this protocol is requested b y a patient or patient’s family member 
participating on the study, the individual should sign a confidentiality agreement.  
A suitable model agreement can be downloaded from: http://ctep.cancer.gov . 
 
2. For a clinica l protocol where there is an investigational Agent used in combination 
with (an)other investigational Agent(s), each the subject of different collaborative 
agreements , the access to and use of data by each Collaborator shall be as follows 
(data pertaining  to such combination use shall hereinafter be referred to as "Multi -
Party Data.):  
 
a. NCI will provide all Collaborators with prior written notice regarding the 
existence and nature of any agreements governing their collaboration with NIH, 
the design of th e proposed combination protocol, and the existence of any 
obligations that would tend to restrict NCI's participation in the proposed 
combination protocol.  
 
b. Each Collaborator shall agree to permit use of the Multi -Party Data from the 
clinical trial by a ny other Collaborator solely to the extent necessary to allow 
said other Collaborator to develop, obtain regulatory approval or commercialize 
its own investigational Agent.  
 
c. Any Collaborator having the right to use the Multi -Party Data from these trials  
must agree in writing prior to the commencement of the trials that it will use 
the Multi -Party Data solely for development, regulatory approval, and 
  PhII-107, NCI# 8628  
  8.21.17 v 70 commercialization of its own investigational Agent.  
 
3. Clinical Trial Data and Results and Raw Data develope d under a Collaborative 
Agreement will be made available exclusively to Collaborator(s), the NCI, and the 
FDA, as appropriate and unless additional disclosure is required by law or court 
order.  Additionally, all Clinical Data and Results and Raw Data will  be collected, 
used, and disclosed consistent with all applicable federal statutes and regulations 
for the protection of human subjects including, if applicable, the  Standards for 
Privacy of Individually Identifiable Health Information  set forth in 45 C.F. R. Part 
164. 
 
4. When a Collaborator wishes to initiate a data request, the request should first be 
sent to the NCI, who will then notify the appropriate investigators (Group Chair for 
Cooperative Group studies, or PI for other studies) of Collaborator's w ish to contact 
them.  
 
5. Any data provided to Collaborator(s) for Phase 3 studies must be in accordance 
with the guidelines and policies of the responsible Data Monitoring Committee 
(DMC), if there is a DMC for this clinical trial.  
 
6. Any manuscripts repo rting the results of this clinical trial must be provided to CTEP 
by the Group office for Cooperative Group studies or by the principal investigator 
for non -Cooperative Group studies for immediate delivery to Collaborator(s) for 
advisory review and comment  prior to submission for publication.  Collaborator(s) 
will have 30 days from the date of receipt for review.  Collaborator shall have the 
right to request that publication be delayed for up to an additional 30 days in order 
to ensure that Collaborator’s c onfidential and proprietary data, in addition to 
Collaborator(s)’s intellectual property rights, are protected.  Copies of abstracts 
must be provided to CTEP for forwarding to Collaborator(s) for courtesy review as 
soon as possible and preferably at least three (3) days prior to submission, but in 
any case, prior to presentation at the meeting or publication in the proceedings.  
Press releases and other media presentations must also be forwarded to CTEP prior 
to release.  Copies of any manuscript, abstract and/or press release/ media 
presentation should be sent to:  
 
Regulatory Affairs Branch, CTEP, DCTD, NCI  
Executive Plaza North, Suite 7111  
Bethesda, Maryland  20892  
FAX 301 -402-1584  
Email: anshers@mail.nih.gov  
 
The Regulatory Affairs Branch will then distribute them to Collaborator(s).  No 
publication, manuscript or other form of public disclosure shall contain any of 
Collaborators confidential/ proprietary information.  
 
  PhII-107, NCI# 8628  
  8.21.17 v 71 13. STATISTICAL CONSIDERATIONS  
13.1. Study Design/End points  
This is a randomized Phase II study of HD -IL2 plus aflibercept vs HD -IL2 alone. The 
randomization is 2:1 in favor of the combination arm , using blocked randomization . 
The randomization is carried out by the central data coordination center. Stratifi cation 
is specified in section 1 3.3, and does not include stratification by center. The primary 
endpoint is progression -free survival. The accrual goal is 105 (70 patients on the 
combination arm,  35 patients on the single agent HD -IL2 arm)  to be accrued o ver 2 
years, with an additional 6 months of follow -up.  
 
This study design has 89% power to detect a 75% increase in the median PFS (7 vs 4 
months), at the 1 -sided 0.10 significance level.  There are no planned interim  analysis 
other than toxicity consider ation s due to the possibility that the aflibercept role may be 
demonstrated in a secondary analysis of the proportion of long -term responders  (e.g., 
>2-yrs). 
 
The primary endpoint of progression -free survival will be measured from data of 
randomization unt il date of progression, death, recurrence or censored at last contact.  
The primary comparison will be based on the log -rank test for comparison of 
progression -free survival , which will be estimated by the Kaplan -Meier method . 
 
Secondary analysis include s overall survival comparison, one-year survival, response 
rate, and toxicity.  Response rate will be estimated and a 95% CI provided for each arm, 
and Cox regression will also be conducted for survival and progression -free survival. 
Survival endpoints will be  evaluated from data of randomization, although we will also 
report on the as -treated populations for comparison.  
  
13.2. Sample Size/Accrual Rate  
We plan 24 months of accrual for 105 patients ( approximately 4-5 patients per  month)  
and a  minimum of 6 months follow-up (no drop outs).   
 
13.3. Stratification Factors  
Randomization will be stratified based on the presence or absence of visceral disease, 
ECOG 0 vs 1, and male vs female. .  
 
13.4. Analysis of Secondary  Endpoints  
  Toxicity Monitoring : HD -IL2 plus Aflibercept arm ( Arm A) : 
 
Toxicity will be primarily be evaluated by examining the number of doses of HD IL-2 
administered during the first cycle of combination  therapy; the percentage of patients 
who receive all 56 doses will also be summarized. Th e toxicity after the sc heduled 10th 
dose of IL -2, the frequency of grade III and IV toxicities, and unusual toxicities will 
also be summarized.  The toxicity profile for the first six patients enrolled on the 
  PhII-107, NCI# 8628  
  8.21.17 v 72 combination arm after the first cycle of high dose IL -2 will be review ed by PI, the 
treating physician or local PI at each of the enrolling institutions, the statistician, and 
the senior investigator at the NCI/CTEP in a conference call. Approval for continuing 
the trial will require a majority consensus to continue in addit ion to requiring approval 
from the PI and the NCI senior investigator.  
 
For safety reasons, accrual to the study will initially be staggered  by at least a week for 
the initial 3 patients . In addition, t oxicity profile will be assessed for each of two coho rts 
of 3 patients after the initial 5 weeks of therapy. If no unexpected toxicity or death 
occurs, the next cohort of three  patients will be allowed to enter the trial.  The same 
toxicity review will occur for cohort 1 as at the end of cohort 2 (see above) . If approval 
is obtained , accrual will be allowed to proceed to the second toxicity analysis point of 
19 patients.   
 
After 19  patients have initiated and completed their first cycle of therapy, an analysis 
of toxicity will be undertaken. Among the initia l 15 patients treated with high dose IL -
2 and aflibercept,  there is high probability of observing rare toxicities  if they exist : 
there is probability of 0. 62 of observing at least one event that occurs at a true rate of 
5%; and probability of 0. 86 of obser ving at least one event that occurs at a true rate of 
10%.  This review will also be conducted with same oversight described above at the 
6 patient time point. An additional review will be mandated upon any treatment -related 
death, and every 6 months.  
 
Based on previous experience with high dose IL2 at the University of Pittsburgh, the 
median number of doses per course 1 (first 2 cycles) as monotherapy [22] is 16 (range 
8-26) and in sequential combination with temozolomide [23] is 15 (range 7 -23). As a 
result, the median number of doses per course 1 will be considered in addition to 
toxicity reported via CTCAE criteria.  
 
Among all 70 patients treated with combination therapy, there is probability of  0.51 of 
observing at least one event that occurs at a true rate of 1%; and probability of 0.9 7 of 
observing at least one event that occurs at a true rate of 5%.  
 
  Correlative Endpoints:  
 
If the agent is promising, we expect to have 70 patients to evaluat e for correlative 
science  on the combination arm . We expect all patients to provide measurements of 
serum VEGF levels and other blood -based biomarkers, with a subset with 
corresponding tissue related correlatives.  Previous data has suggested that high VEG F 
levels predict lower response to IL -2, With a minimum expected balance of 16 
(responders) vs 54 (non -responder s), there will be a minimum of 9 6% power to detect 
a one standard deviation difference  (after aflibercept therapy)  in the VEGF levels in 
respo nders vs non -responders, with a one -sided type I error of 0.05  (NOTE: we expect 
at least 16 responders out of the 70 patients evaluable for correlative science on the 
combination arm. If more are obtained, the statistical operating characteristics improve 
due to better balance between responders and non -responders) . We will also compare 
  PhII-107, NCI# 8628  
  8.21.17 v 73 the mean baseline VEGF levels in responders and non -responders and provide a 95% 
confidence interval as part of our exploratory analysis.  
 
Correlative endpoints will also be  explored using multivariate Cox regression, 
exploring the impact of both baseline VEGF levels and VEGF levels after aflibercept 
therapy, while adjusting for known patient characteristics that impact survival.  
 
Other correlative endpoints will also be expl ored, including evaluating the biological 
correlatives in the HD -IL2 alone arm, and while no attempt will be made to adjust for 
multiple comparisons for additional correlative endpoints, any conclusions will be 
stated as exploratory and in the context of a  randomized phase II  study.   
 
13.5. Reporting and Exclusio ns 
 
13.5.1.  Evaluation of toxicity.  All patients will be evaluable for toxicity from th e time of 
their first treatment.  
 
13.5.2.  Evaluation of response .  All patients included in the study must be assessed for 
response  to treatment, even if there are major protocol treatment deviations or if 
they are ineligible.  Each patient will be assigned one of the following categories:  
1) complete response, 2) partial response, 3) stable disease, 4) progressive disease, 
5) early death from malignant disease, 6) early death from toxicity, 7) early death 
because of other cause, or 9) unknown (not assessable, insufficient data).  [Note:  
By arbitrary convention, category 9 usually designates the “unknown” status of any 
type of data i n a clinical database.]  
 
All of the patients who met the eligibility criteria (with the possible exception of 
those who received no study medication) should be included in the main analysis 
of the response rate.  Patients in response categories 4 -9 should be considered to 
have a treatment failure  (disease progression).  Thus, an incorrect treatment 
schedule or drug administration does not result in exclusion from the analysis of 
the response rate.  Precise definitions for categories 4 -9 will be protocol spe cific.  
 
All conclusions will be based on all eligible patients.  Subanalyses may then be 
performed on the basis of a subset of patients, excluding those for whom major 
protocol deviations have been identified (e.g., early death due to other reasons, 
early  discontinuation of treatment, major protocol violations, etc.).  However, these 
subanalyses will not serve as the basis for drawing conclusions concerning 
treatment efficacy, and the reasons for excluding patients from the analysis  will be 
clearly reporte d.  The 95% confidence intervals will also be provided for both 
survival and response estimates.   
 
14. CCCP POLICIES FOR MONITORING CONSORTIUM TRIALS  
The protocol principal investigator (PI) is responsible for monitoring the conduct and 
progress of this Phase I trial, including the ongoing review of accrual, data and toxicities, 
  PhII-107, NCI# 8628  
  8.21.17 v 74 as well as the accumulation of reported adverse events from other trials testing the same 
drug(s).  The participating clinicians and their designees are responsible for timely 
submissio n of adverse event reports (see Section 7.0) and case report forms.  The Data 
Coordinating Center for the CCCP Consortium is responsible for providing the PI with 
access to the submitted case report form data in summary and detail in a timely fashion.   
Although the PI is responsible for evaluating the cumulative reported adverse events and 
the impact that these have on the continued conduct of the trial, it is the Data Coordinating 
Center of the CCCP that distributes all submitted SAE reports to the approp riate 
individuals, including the local protocol principal investigators, at each of the participating 
institutions.   
 
The Data Coordinating Center posts a summary (accrual, toxicities, and responses) of each 
CCCP initiated trial on the CCCP website.  In t his way, each PI has access to up -to-date 
information on the status of his or her trial.  In consultation with the collaborating 
statistician, the PI is responsible for review of:  
 
(a) for Phase I trials, all dose limiting toxicities and decisions regardin g dose 
escalation, expansion, as well as decisions to terminate escalation, and  
(b) for Phase II trials, the toxicities and therapeutic endpoints referred to in the 
statistical plan.  
 
The Data Coordinating Committee meets monthly to review data management  and data 
quality issues – completeness of data submissions as well as accuracy in terms of built -in, 
computerized logic checks.  Any issues identified and the corrective plans are presented to 
the Internal Committee and at the next CCCP teleconference mee ting for review and 
approval.  
 
Oversight  
Oversight of the conduct of CCCP trials occurs at several levels:  
 
1. The Data Coordinating Center for the CCCP flags all trials that are approaching a 
decision in terms of toxicity (for both Phase I and Phase II trial s) or responses (for 
Phase II trials).  Decisions are made by the PI with input from the statistician and 
discussion with the principal investigator of the funding mechanism (U01 
Cooperative Agreement or N01 Contract, as appropriate) or his or her designee , and 
are communicated to the participating centers by the CCCP Data Coordinating 
Center. At the monthly teleconferences, the accrual of each open protocol is 
reviewed.  
 
2. For CTEP sponsored Phase I trials, data are reported to the NCI -designated clinical 
trials monitoring service (CTMS) which will audit patients’ records on each 
protocol – at each CCCP institution; this audit is initiated by CTEP.  For all other 
CCCP trials, the CCCP will contract with Theradex to audit patient records at each 
CCCP instituti on. 
 
  PhII-107, NCI# 8628  
  8.21.17 v 75 3. An independent CCCP DSMC will review CCCP trials every 6 months. This DSMC 
will consist of 3 voting members (2 medical oncologists or hematologists involved 
in Phase I/II cancer clinical trials but not participating in CCCP studies, and a 
statistician ) and a non -voting CCCP statistician.   
 
a. DSMC meetings will take place twice a year.  Additional meetings will be 
convened if necessary.  
b. This DSMC will review each CCCP trial in terms of accrual, toxicity/safety, and  
adherence to trial design, audit resul ts, and likelihood of successful completion.   
c. The DSMC will report to the CCCP leadership.  
  PhII-107, NCI# 8628  
  8.21.17 v 76 15. REFERENCES  
1. Tarhini, A.A. and S.S. Agarwala, Cutaneous melanoma: available therapy for metastatic 
disease.  Dermatol Ther, 2006. 19(1): p. 19 -25. 
2. Atkins, M.B., et al., High -dose recombinant interleukin 2 therapy for patients with 
metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.  J Clin 
Oncol, 1999. 17(7): p. 2105 -16. 
3. Investigator'sBrochure, [AFLIBERCEPT (VEGF Tra p, AVE0005 )] (2009). Regeneron 
Pharmaceuticals,Inc., Tarrytown, NY and Aventis Pharmaceuticals Inc., Bridgewater, 
NJ. Edition 9. May 1, , 2009.  
4. Tarhini, A.A. and J.M. Kirkwood. Phase II study of aflibercept (VEGF trap) in recurrent 
inoperable stage III or stage IV melanoma of cutaneous or ocular origin. ASCO Annual 
Meeting; Abs ID 9028  
2009.  
5. Smith, K.A., Interleukin -2: inception, impact, and implications.  Science, 1988. 
240(4856): p. 1169 -76. 
6. Rosenberg, S.A., et al., Regression of established pulm onary metastases and 
subcutaneous tumor mediated by the systemic administration of high -dose recombinant 
interleukin 2.  J Exp Med, 1985. 161(5): p. 1169 -88. 
7. Dutcher, J.P., et al., A phase II study of interleukin -2 and lymphokine -activated killer 
cells i n patients with metastatic malignant melanoma.  J Clin Oncol, 1989. 7(4): p. 477 -
85. 
8. Parkinson, D.R., et al., Interleukin -2 therapy in patients with metastatic malignant 
melanoma: a phase II study.  J Clin Oncol, 1990. 8(10): p. 1650 -6. 
9. Rosenberg, S.A. , et al., Treatment of 283 consecutive patients with metastatic melanoma 
or renal cell cancer using high -dose bolus interleukin 2.  Jama, 1994. 271(12): p. 907 -13. 
10. Atkins, M.B., et al., High -dose recombinant interleukin -2 therapy in patients with 
metast atic melanoma: long -term survival update.  Cancer J Sci Am, 2000. 6 Suppl 1 : p. 
S11-4. 
11. Schwartzentruber, D.J., High -dose interleukin -2 is an intensive treatment regardless of 
the venue of administration.  Cancer J, 2001. 7(2): p. 103 -4. 
12. Rosenberg, S. A., et al., Prospective randomized trial of high -dose interleukin -2 alone or 
in conjunction with lymphokine -activated killer cells for the treatment of patients with 
advanced cancer.  J Natl Cancer Inst, 1993. 85(8): p. 622 -32. 
13. Figlin, R.A., et al., Multicenter, randomized, phase III trial of CD8(+) tumor -infiltrating 
lymphocytes in combination with recombinant interleukin -2 in metastatic renal cell 
carcinoma.  J Clin Oncol, 1999. 17(8): p. 2521 -9. 
14. Sabatino, M., et al., Serum vascular endothelial grow th factor and fibronectin predict 
clinical response to high -dose interleukin -2 therapy.  J Clin Oncol, 2009. 27(16): p. 2645 -
52. 
15. Kerbel, R.S., Tumor angiogenesis.  N Engl J Med, 2008. 358(19): p. 2039 -49. 
16. Folkman, J., Tumor angiogenesis: therapeutic implications.  N Engl J Med, 1971. 
285(21): p. 1182 -6. 
17. Tas, F., et al., Circulating serum levels of angiogenic factors and vascular endothelial 
growth factor receptors 1 and 2 in melanoma patients.  Melanoma Res, 2006. 16(5): p. 
405-11. 
18. Gabrilovich, D.I., et al., Production of vascular endothelial growth factor by human 
  PhII-107, NCI# 8628  
  8.21.17 v 77 tumors inhibits the functional maturation of dendritic cells.  Nat Med, 1996. 2(10): p. 
1096 -103. 
19. Ohm, J.E., et al., VEGF inhibits T -cell development and may contribute to tumor -induced 
immune suppression.  Blood, 2003. 101(12): p. 4878 -86. 
20. Eisenhauer, E.A., et al., New response evaluation criteria in solid tumours: revised 
RECIST guideline (version 1.1).  Eur J Cancer, 2009. 45(2): p. 228 -47. 
21. Schwartzentruber, D.J., Guidelines  for the safe administration of high -dose interleukin -2. 
J Immunother, 2001. 24(4): p. 287 -93. 
22. Tarhini AA, Kirkwood JM, Gooding WE, Cai C, Agarwala SS, Durable Complete 
Responses With High -Dose Bolus Interleukin -2 in Patients With Metastatic Melanoma 
Who Have Experienced Progression After Biochemotherapy.  J Clin Oncol, 2007. 25(25): 
p. 0000 -0000.  
23. Tarhini, A.A., et al., A phase 2 trial of sequential temozolomide chemotherapy followed 
by high -dose interleukin 2 immunotherapy for metastatic melanoma.  Cancer, 2008. 
113(7): p. 1632 -40. 
 
 
 
  
 
 
 
  PhII-107, NCI# 8628  
  8.21.17 v 78 APPENDIX A  – Performance Status Criteria  
 
 
 
ECOG Performance Status Scale  
  
Karnofsky Performance Scale  
Grade  Descriptions  Percent  Description  
0 Normal activity.  Fully active, able 
to carry on all pre -disease 
performance without restriction.  100 Normal, no complaints, no evidence 
of disease.  
90 Able to carry on normal activity; 
minor signs or symptoms of disease.  
1 Symptoms, but ambulatory.  
Restricted in physically strenuous 
activity, but ambulatory and abl e 
to carry out work of a light or 
sedentary nature (e.g., light 
housework, office work).  80 Normal activity with effort; some 
signs or symptoms of disease.  
70 Cares for self, unable to carry on 
normal activity or to do active work.  
2 In bed <50% of the  time.  
Ambulatory and capable of all 
self-care, but unable to carry out 
any work activities.  Up and about 
more than 50% of waking hours.  60 Requires occasional assistance, but 
is able to care for most of his/her 
needs.  
50 Requires considerable assista nce and 
frequent medical care.  
3 In bed >50% of the time.  Capable 
of only limited self -care, confined 
to bed or chair more than 50% of 
waking hours.  40 Disabled, requires special care and 
assistance.  
30 Severely disabled, hospitalization 
indicated.  D eath not imminent.  
4 100% bedridden.  Completely 
disabled.  Cannot carry on any 
self-care.  Totally confined to bed 
or chair.  20 Very sick, hospitalization indicated. 
Death not imminent.  
10 Moribund, fatal processes 
progressing rapidly.  
5 Dead.  0 Dead . 
 
 
 
 
 
 
 
 
 
 
  PhII-107, NCI# 8628  
  8.21.17 v 79 APPENDIX B  – CTEP M ulticenter Guidelines  
 
If an institution wishes to collaborate with other participating institutions in performing a 
CTEP sponsored research protocol, then the following guidelines must be followed.  
 
Responsibility of the P rotocol Chair  
• The Protocol Chair will be the single liaison with the CTEP Protocol and Information 
Office (PIO).  The Protocol Chair is responsible for the coordination, development, 
submission, and approval of the protocol as well as its subsequent amend ments.  The 
protocol must not be rewritten or modified by anyone other than the Protocol Chair.  There 
will be only one version of the protocol, and each participating institution will use that 
document.  The Protocol Chair is responsible for assuring that  all participating institutions 
are using the correct version of the protocol.  
• The Protocol Chair is responsible for the overall conduct of the study at all participating 
institutions and for monitoring its progress.  All reporting requirements to CTEP are  the 
responsibility of the Protocol Chair.  
• The Protocol Chair is responsible for the timely review of Adverse Events (AE) to assure 
safety of the patients.  
• The Protocol Chair will be responsible for the review of and timely submission of data for 
study an alysis.  
 
Responsibilities of the Coordinating Center  
• Each participating institution will have an appropriate assurance on file with the Office for 
Human Research Protection (OHRP), NIH.   The Coordinating Center is responsible for 
assuring that each partici pating institution has an OHRP assurance and must maintain 
copies of IRB approvals from each participating site.  
•  Prior to the activation of the protocol at each participating institution, an OHRP form 310 
(documentation of IRB approval) must be submitted  to the CTEP PIO.  
• The Coordinating Center is responsible for central patient registration.  The Coordinating 
Center is responsible for assuring that IRB approval has been obtained at each participating 
site prior to the first patient registration from that  site. 
• The Coordinating Center is responsible for the preparation of all submitted data for review 
by the Protocol Chair.  
• The Coordinating Center will maintain documentation of AE reports.  There are two 
options for AE reporting: (1) participating institut ions may report directly to CTEP with a 
copy to the Coordinating Center, or (2) participating institutions report to the Coordinating 
Center who in turn report to CTEP.  The Coordinating Center will submit AE reports to 
the Protocol Chair for timely review . 
• Audits may be accomplished in one of two ways:  (1) source documents and research 
records for selected patients are brought from participating sites to the Coordinating Center 
for audit, or (2) selected patient records may be audited on -site at participa ting sites.  If the 
NCI chooses to have an audit at the Coordinating Center, then the Coordinating Center is 
responsible for having all source documents, research records, all IRB approval documents, 
NCI Drug Accountability Record forms, patient registrati on lists, response assessments 
scans, x -rays, etc. available for the audit.  
 
  PhII-107, NCI# 8628  
  8.21.17 v 80 Inclusion of Multicenter Guidelines in the Protocol  
• The protocol must include the following minimum information:  
➢ The title page must include the name and address of each particip ating institution and 
the name, telephone number and e -mail address of the responsible investigator at each 
participating institution.  
➢ The Coordinating Center must be designated on the title page.  
➢ Central registration of patients is required.  The procedur es for registration must be 
stated in the protocol.  
➢ Data collection forms should be of a common format.  Sample forms should be 
submitted with the protocol.  The frequency and timing of data submission forms to the 
Coordinating Center should be stated.  
➢ Describe how AEs will be reported from the participating institutions, either directly to 
CTEP or through the Coordinating Center.  
➢ Describe how Safety Reports and Action Letters from CTEP will be distributed to 
participating institutions.   
 
Agent Ordering  
• Except in very unusual circumstances, each participating institution will order DCTD -
supplied investigational agents directly from CTEP.  Investigational agents may be ordered 
by a participating site only after the initial IRB approval for the site has been f orwarded by 
the Coordinating Center to the CTEP PIO.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  PhII-107, NCI# 8628  
  8.21.17 v 81 APPENDIX C  – CCCP Registration Procedures for Phase II Trials  
 
1. Registrations for Phase II protocols must be made through the California Cancer 
Consortium office at the City of  Hope between the hours of 8:30 a.m. to 4:30 p.m., Monday 
through Friday (except holidays).  
 
2. Patients must be registered within 3 days prior to initiation of protocol therapy.  
 
3. A patient failing to meet all protocol requirements may not be registered .  If you have any 
questions regarding eligibility, contact the City of Hope Data Coordinating Center (DCC) 
at (626) 256 -HOPE (4673),  extension 65928.  
 
4. Prestudy laboratory tests, scans and x -rays must be completed prior to registration 
according to stud y calendar/protocol.  
 
5. Patients must sign an informed consent prior to registration.  
 
6. Confirm that the patient meets all inclusion and exclusion eligibility criteria for a protocol.  
 
7. Complete the Eligibility Checklist.   
 
8. Verify that all require d prestudy tests were performed.  
 
9. Fax the completed Eligibility Checklist, signed and dated informed consent, pathology 
report, and relevant laboratory results to the City of Hope Consortium Coordinator for 
confirmation of eligibility.  The FAX number i s (626) 256 -8654.  
 
10. Call the City of Hope Consortium Coordinator at (626) 256 -HOPE (4673), extension 65928  
to confirm the FAX arrival. If the Consortium Coordinator is not in the office, have them 
paged at (626) 423 -5365.  
 
11. If the patient qualifies,  the City of Hope Consortium Coordinator will call the registering 
institution to complete the registration/randomization procedure and assign the patient's 
study ID number.   
 
12. Once a patient has been registered, the Data Coordinating Center will provi de a 
"Confirmation of Registration" to the center registering the patient.  
 
 
For questions regarding eligibility call City of Hope California Cancer Consortium, Data 
Coordinating Center  
(626) 256 -HOPE (4673), extension 65928  
 
 
 
 
  PhII-107, NCI# 8628  
  8.21.17 v 82 APPENDIX D – CCCP Specimen  Submission Form s 
 
Please contact the Data Coordinating Center at cccp@coh.org  for the CCCP Specimen Submission 
Form.  The form will be emailed to the participating institution when the study has been activated.   
 
An a dditional form called “PhII -107 Research Specimen Submission Form” will also need to be 
completed and will be distributed to activated.  If a copy is needed, please contact the DCC at 
cccp@coh.org .  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  PhII-107, NCI# 8628  
  8.21.17 v 83  
 
 
 
 
APPENDIX E – NYHA functional classification system  
 
 
Class  Functional Capacity  Objective Assessment  
I Patients with cardiac disease but without resulting limitations of 
physical activity.  Ordinary physical activity does not cause un due 
fatigue, palpitation, dyspnea, or anginal pain.  No objective evidence of 
cardiovascular disease.  
II Patients with cardiac disease resulting in slight limitation of 
physical activity.  They are comfortable at rest.  Ordinary physical 
activity results i n fatigue, palpitation, dyspnea, or anginal pain.  Objective evidence of 
minimal cardiovascular 
disease.  
III Patients with cardiac disease resulting in marked limitation of 
physical activity.  They are comfortable at rest.  Less than 
ordinary activity caus es fatigue, palpitation, dyspnea, or anginal 
pain.  Objective evidence of 
moderately severe 
cardiovascular disease.  
IV Patients with cardiac disease resulting in inability to carry on any 
physical activity without discomfort.  Symptoms of heart failure 
or the anginal syndrome may be present even at rest.  If any 
physical activity is undertaken, discomfort is increased.  Objective evidence of 
severe cardiovascular 
disease.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  PhII-107, NCI# 8628  
  8.21.17 v 84 APPENDIX F - Labeling Instructions for Serum Samples for Regeneron  (Anti -
Aflibercept Antibody Testing)  
 
 
1. Verify that the number directly under the Barcode on the label to be affixed to the vial 
matches the corresponding label to be affixed to the shipping paperwork.  
 
2. Complete the information required on the visit -specifi c label: Subject ID.  Please note 
that you will need to complete the following additional fields if you are using an 
Unscheduled Visit Label: Visit #, Date, Time, and Sample Type (serum or plasma).  
 
 
 
Visit -Specific Specimen Label                         Unscheduled Visit Specimen Label  
 
 
 
 
                                         
                                                                                 Barcode  
 
                                                                      Complete these fields  
 
 
 
 
 
 
 
 
3. Remove label from backing, turn label sideways (to the left), and apply the bottom of 
the label to the cryovial first.  Make sure that the label does not cover the threading on 
the top of the cryovial.  Wrap remaining portion of label in a clockwise direction around 
cryovial and be sure that the label’s bar code runs vertically along the cryovial.  Please 
refer to the picture of correctly labeled cryovial on next page.  
 REGENERON  
Pharmaceuticals, Inc  
                                   
SAG  
VEGFT -RA-0402 -
00100004  
        
 
 
Subject ID  _ _ _ _ _ _  
 
__ 
 
Visit 1, Timepoint: 
2hr 
 
PK 
Hu Plasma  REGENERON  
Pharmaceuticals, Inc  
                                   
SAG  
VEGFT -RA-0402 -
00100004  
        
 
 
Subject ID  _ _ _ _ _ _  
 
__ 
 
Visit # 
____________  
Date 
______________  
Time___________
___ 
Sample 
Type________  
  PhII-107, NCI# 8628  
  8.21.17 v 85                                                     1.8 mL cryovial  
 
                                                                           Top 
 
 
 
 
                                                                                                             
 
 
 
 
                                                                                          Bottom  
                                                                   
       
 
 
 
 
 
Correctly Labeled Cryovial with Barcode in Vertical Direction  
 
 
                                                  Top 
 
 
 
 
 
 
                                                                                                      Barcode  
 
 
 
 
                                              Bottom  
 
 
Please note that the label must appear this way to be read by the label scanner.  
 
 
REGENERON  
Pharmaceuticals, Inc  
                                   
SAG  
IL1T -RA-0402 -
00100004  
        
 
Subject ID   _ _ _ _ _  
 
Subject Initials __ __  
Visit 1, Timepoint: 
2hr 
 
PK 
Hu Serum  
 REGENERON  
Pharmaceuticals, Inc                       
SAG  
IL1T -RA-0402 -00100004  
        
 
 
Subject ID    _ _ _ _ _ _  
 
Subject Initials  __ __ 
__ 
  PhII-107, NCI# 8628  
  8.21.17 v 86 WHAT TO DO IN  CASE OF MISTAKES  
 
If you accidentally used the wrong label  for a cryovial, please:  
 
• Remove the incorrect label and re -label the cryovial with the correct label.  If you 
do not have an extra label for a particular visit, you should use an Unscheduled 
Visit  Label  and complete the required information.  Please save the incorrect label 
and attach it to the shipping list with a written explanation of the error.  
 
 
If you made a mistake  on the label, such as writing the wrong subject initials or date, please:  
 
• Cross out the wrong information and write the correct information on the label.  
Make sure that you initial and date the cross -out.  If you cannot correct the label in 
a legible fashion, use an Unscheduled Visit Label (see top of Page 1).  
  PhII-107, NCI# 8628  
  8.21.17 v 
 87 APPENDIX G - COL LECTION OF SERUM SAMPLES for Regeneron (Anti -Aflibercept Antibody Testing)  
 
SERUM  Samples for Regeneron  
 
 
Anti -VEGF Trap Antibody Samples  
 
  
 
 
 
                                 
     5 mL plain red top tube                                                  2 cryovials with 0.8 mL  serum  each 
 
Note:  1. Collect one red top tube for each sample.  
2. Only one cryovial per subject per time point should be sent with the initial scheduled shipment.  
3.  Refer to SERUM Sa mple Collection and Preparation inst ructions for additional details.
1.  Immediately invert tube 4 times then 
allow 30 min. for serum to clot.  Centrifuge 
at 2000 x g for 15 min. at room temp. within 
1 hour of collection  
2.  Within 30 min. draw 
off serum very slowly 
with transfer pipette  3. Pipette 0.8 mL of serum into 
each of 2 separate labeled plastic 
cryovials and store frozen at -
20°C  
ANTIBODY 
PRIMARY  
                                   
 
 
 
Subject ID    _ 
_ _ _ _ _  
 
Subject 
Initials  __ __ 
__ ANTIBODY 
DUP  
 
Pharmaceu
ticals, Inc  
                                   
SAG  
1.1.1. I
L
1
T
-
R
A
-
0
4
0
2
-
0
0
1
0
0
0
0
4 
       
 
 
 
Subject ID    
_ _ _ _ _ _  
 
Subject 
Initials  __ 
__ __ Duplicate  
Samples  
Storage 
box 
(Freezer)  
Primary 
Samples  
Storage 
box 
(Freezer)  
  PhII-107, NCI# 8628  
  8.21.17 v 
 88 APPENDIX H - Patient Blood Pressure Monitoring Diary (for patients on 
Arm A receiving Aflibercept)  
 
NOTE: This optional diary is strongly recommended to be used as more frequent blood pre ssure 
monitoring than what is required in the protocol and can be used at the discretion of the treating 
physician.  
 
Diary Card  
Blood Pressure Monitoring  
 
Dates: ____/____/____ to ____/____/____  
 
Patient Number:         Patient Initials:   
 
Hypertension is a known and potentially serious adverse event associated with aflibercept treatment. It is 
recommended that you have your blood pressure monitored as follows:  
• At least twice weekly during the first 5 cycles of aflibercept therapy (Course 1 of protocol thera py) and prior 
to each infusion of aflibercept.  
• At least once weekly during each subsequent cycle of aflibercept therapy.  
• If the blood pressure is not well controlled, then it should monitored more frequently.  
 
Blood pressure is typically recorded as two n umbers, written as a ratio. The top number  (systolic) , which is also the 
higher of the two numbers, measures the pressure in the arteries when the heart beats (when the heart muscle contracts). 
The bottom number  (diastolic) , which is also the lower of the two numbers, measures the pressure in the arteries 
between heartbeats (when the heart muscle is resting between beats and refilling with blood).  
 
You should contact your physician’s office if your blood pressure exceeds 140 mmHg (systolic) or 90 mmHg 
(dias tolic) at any time and are encouraged to contact your physician if you are concerned about any symptoms that 
may be associated with high blood pressure ( e.g., headache).  
 
You should seek immediate medical advice if your blood pressure exceeds 180 mmHg (sy stolic) or 105 mmHg 
(diastolic) at any time and are encouraged to contact you physician if they are concerned about any symptoms that 
may be associated with high blood pressure ( e.g., headache).  
  
While you are receiving treatment with aflibercept , the ea rly initiation of antihypertensive treatment to 
minimize more severe or persistent hypertension is considered an important precautionary measure to avoid 
potentially serious complications.  
 
When  you are  receiving IL2  on Arm A , the blood pressure medication s should be managed 
as follows:  
• On the day of admission, the morning blood pressure medications should be taken, anticipating 
that the first dose of IL2 is given that evening . Otherwise, if the first dose of IL2 is expected to be 
given during the day, then  the morning blood pressure medications should be held.  
• If the first dose of IL2 is anticipated to be given in the evening of the day of admission, then the 
blood pressure medications should be held for that evening and throughout IL2 treatment unless 
otherwise specified by the treating physician  
  PhII-107, NCI# 8628  
  8.21.17 v 
 89 • Upon completion of IL2 therapy, the blood pressure medications should restarted as soon as the 
IL2 induced hypotension (low blood pressure) has resolved. Most importantly, the blood pressure 
medications should be restarted before the patient is discharged home.  
• Following home discharge from inpatient IL2 therapy, you should have the blood pressure 
monitored at least twice weekly and contact your physician’s office if your blood pressure exceeds 
140 mmHg (systolic)  or 90 mmHg (diastolic) as noted above.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient sequence number:                                                           
  PhII-107, NCI# 8628  
  8.21.17 v 
 90   
 
Blood 
Pressure  
No.  
 
 
Date  
  
TIME  
Record Time of Blood Pressure  
(Circle AM or PM)  
 
 
    BP           TIME      circle AM/PM  Use the space below to make 
notes about things you would 
like to tell the doctor (include 
any unusual symptoms you 
experience, other medicine you 
have taken and anything else 
you think may be of interest.  Month  Day Year  
1        : AM  PM   
2        : AM  PM   
3        : AM  PM   
4        : AM  PM   
5        : AM  PM   
6        : AM  PM   
7        : AM  PM   
8        : AM  PM   
9        : AM  PM   
10        : AM  PM   
11        : AM  PM   
12        : AM  PM   
13        : AM  PM   
14        : AM  PM   
15        : AM  PM   
16        : AM  PM   
17        : AM  PM   
18        : AM  PM   
19        : AM  PM   
20        : AM  PM   
21        : AM  PM   
22        : AM  PM   
23        : AM  PM   
24        : AM  PM   
25        : AM  PM  
26        : AM  PM   
27        : AM  PM   
28        : AM  PM   
29        : AM  PM   
30        : AM  PM   